{"gene":"CTSK","run_date":"2026-04-28T17:28:53","timeline":{"discoveries":[{"year":1996,"finding":"Pycnodysostosis (autosomal recessive osteosclerosis) is caused by loss-of-function mutations in cathepsin K (CTSK), establishing that CTSK is a lysosomal cysteine protease essential for osteoclast-mediated bone resorption; nonsense, missense, and stop-codon mutations were identified in affected patients.","method":"Genetic linkage mapping, Sanger sequencing of patient DNA, transient expression of mutant cDNA with Western blot to confirm absence of protein","journal":"Science","confidence":"High","confidence_rationale":"Tier 1-2 — foundational disease-gene identification, multiple mutation types, protein expression validation; independently replicated across many subsequent studies","pmids":["8703060"],"is_preprint":false},{"year":1995,"finding":"Human cathepsin K was molecularly cloned and identified as a novel cysteine proteinase of the papain superfamily, predominantly expressed in osteoclasts and osteoclastomas, implicating it as the major protease in osteoclastic bone resorption.","method":"cDNA library screening using rabbit OC-2 probe, Northern blot analysis of tissue distribution","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 — original cloning with expression characterization; independently confirmed by multiple labs","pmids":["7818555","7576232","7805878"],"is_preprint":false},{"year":1996,"finding":"Recombinant cathepsin K is a cysteine protease that degrades type I collagen and osteonectin (bone matrix proteins) in vitro; it is activated upon removal of its inhibitory pro-sequence, is inhibited by E-64 and leupeptin but not by pepstatin or EDTA, and cleaves fluorogenic peptide substrates.","method":"Baculovirus expression, purification, in vitro enzyme activity assays with fluorogenic peptides, collagen degradation assay, inhibitor profiling","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro with multiple substrates and inhibitor characterization","pmids":["8647860"],"is_preprint":false},{"year":1997,"finding":"Crystal structure of human cathepsin K complexed with a potent inhibitor was determined, revealing the active-site architecture of this papain-family cysteine protease.","method":"X-ray crystallography","journal":"Nature structural biology","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with functional inhibitor complex","pmids":["9033587"],"is_preprint":false},{"year":1997,"finding":"CTSK gene was mapped to chromosome 1q21 by fluorescence in situ hybridization; genomic organization established as 8 exons/7 introns spanning ~12.1 kb; a single transcription start site 49 bp upstream of the initiator Met was identified; the 5' flanking region lacks canonical TATA/CAAT boxes, suggesting non-canonical transcriptional regulation.","method":"FISH, PCR on genomic DNA, P1 clone isolation, ribonuclease protection assay, 5' RACE","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 2 — direct experimental mapping and promoter characterization","pmids":["9143491"],"is_preprint":false},{"year":1997,"finding":"Cathepsin K protein is specifically localized to osteoclasts within bone tissue; in actively resorbing osteoclasts, immunostaining localizes cathepsin K at the ruffled border, and in giant cell tumors it is found in lysosomal vacuoles that fuse with the cell membrane.","method":"In situ hybridization and immunohistochemistry on bone and giant cell tumor sections","journal":"Bone","confidence":"High","confidence_rationale":"Tier 2 — direct localization with functional spatial context (ruffled border during active resorption); replicated across multiple studies","pmids":["9028530"],"is_preprint":false},{"year":1998,"finding":"SCCA1 (squamous cell carcinoma antigen 1), a serpin, is a potent cross-class inhibitor of cathepsin K, acting with 1:1 stoichiometry and second-order rate constants ≥1×10⁵ M⁻¹s⁻¹, forming stable complexes via a mechanism similar to serpin-serine protease interactions involving cleavage at the reactive site loop.","method":"Kinetic analysis (second-order rate constants, stoichiometry, complex stability), SDS-PAGE to detect stable inhibitor-protease complex","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — rigorous kinetic analysis with mechanistic characterization of inhibitor-enzyme interaction","pmids":["9548757"],"is_preprint":false},{"year":1999,"finding":"Complete mouse Ctsk gene was characterized (8 exons, 7 introns, ~10.1 kb), showing conserved exon sizes with the human gene; Ctsk is located ~4.5 kb downstream of the Arnt gene on mouse chromosome 3.","method":"Genomic cloning, sequence analysis, chromosomal mapping","journal":"Matrix biology","confidence":"Medium","confidence_rationale":"Tier 2 — direct genomic characterization; single study","pmids":["10372556"],"is_preprint":false},{"year":1999,"finding":"CTSK mutations that reduce cathepsin K protein to virtually absent levels cause pycnodysostosis, while ~50-80% reduced protein levels (in heterozygous parents) have no phenotypic effect, establishing a threshold for cathepsin K in bone resorption.","method":"DNA sequencing of patient/family members, Western blot for protein expression levels","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 — protein quantification in affected individuals and carrier parents with clear genotype-phenotype dose-response","pmids":["10491211"],"is_preprint":false},{"year":2000,"finding":"Recombinant human cathepsin K cleaves the trivalently cross-linked ICTP (carboxyterminal telopeptide of type I collagen) at two sites between the phenylalanine-rich region and the cross-link, destroying ICTP immunoreactivity; MMP-9, MMP-1, and MMP-13 do not have this effect, distinguishing cathepsin K-mediated from MMP-mediated collagen degradation in bone.","method":"In vitro proteolytic cleavage assay with recombinant cathepsin K and MMPs, immunochemical detection of ICTP degradation products","journal":"Bone","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with multiple proteases compared; identifies specific cleavage sites","pmids":["10719280"],"is_preprint":false},{"year":2001,"finding":"Cathepsin K is expressed in synovial fibroblasts (SFs) in rheumatoid arthritis and is the critical protease for SF-mediated intralysosomal collagen degradation; co-culture of SFs on cartilage showed collagen fibril phagocytosis and lysosomal hydrolysis blocked by cathepsin K inhibitor but not by inhibitors of cathepsins L, B, and S. Cathepsin K also has potent aggrecan-degrading activity, and cathepsin K-generated aggrecan fragments potentiate its own collagenolytic activity.","method":"Immunostaining of RA joint specimens, primary SF cell culture, co-culture on cartilage disks, selective protease inhibitors, collagen degradation assay","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including selective inhibition in cell culture and cartilage co-culture; identifies novel substrate (aggrecan) and positive feedback mechanism","pmids":["11733367"],"is_preprint":false},{"year":2002,"finding":"Cathepsin K collagenase activity requires complex formation with chondroitin sulfate glycosaminoglycans; the active complex is an oligomer of five cathepsin K and five chondroitin sulfate molecules. Monomeric cathepsin K has no collagenase activity but retains gelatinase activity. The Y212C pycnodysostosis-causing mutant cannot form these complexes and therefore lacks collagenase activity despite retaining gelatinase activity.","method":"In vitro complex formation assay, collagen and gelatin degradation assays, analysis of pycnodysostosis mutant Y212C","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro with mutant validation linking complex formation to disease; mechanistically definitive","pmids":["12039963"],"is_preprint":false},{"year":2003,"finding":"Chondroitin sulfate and keratan sulfate (GAGs predominant in bone and cartilage) enhance cathepsin K's collagenolytic activity, while dermatan sulfate, heparan sulfate, and heparin selectively inhibit it. Complex formation with GAGs is unique to cathepsin K among papain-like cysteine proteases; cathepsins L and S do not form these complexes and their collagenase activity is inhibited by GAGs at 37°C.","method":"In vitro collagen degradation assays with different GAGs, comparative analysis across cathepsin family members","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — rigorous in vitro reconstitution with structure-activity analysis across multiple GAGs and cathepsins","pmids":["14645229"],"is_preprint":false},{"year":2004,"finding":"p38 MAP kinase is required for maximal RANKL-induced cathepsin K gene expression during osteoclastogenesis; RANKL-induced NFATc1 is phosphorylated by activated p38 MAP kinase, then forms a complex with PU.1 in osteoclast nuclei; NFATc1, PU.1, and MITF synergistically enhance cathepsin K promoter activity.","method":"Reporter gene assay with cathepsin K 5'-deletion constructs, overexpression in RAW264 cells, p38-specific inhibitor (SB203580), nuclear localization studies","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — promoter dissection, transcription factor overexpression, chemical inhibition, nuclear complex formation; multiple orthogonal methods","pmids":["15304486"],"is_preprint":false},{"year":2004,"finding":"Cathepsin K plays a pivotal role in lung matrix homeostasis; CTSK-/- mice develop significantly more extracellular matrix deposition and fibrosis after bleomycin challenge. Primary lung fibroblasts from CTSK-/- mice show decreased collagenolytic activity, and human pulmonary fibroblasts upregulate cathepsin K activity during activation.","method":"Bleomycin-induced fibrosis model in Ctsk knockout mice, primary fibroblast collagenolytic activity assays, gene expression analysis","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 — KO mouse model with defined phenotype plus in vitro fibroblast activity assays; multiple orthogonal methods","pmids":["15161653"],"is_preprint":false},{"year":2005,"finding":"ARNT transcripts read through the ARNT-CTSK intergenic region and extend into CTSK intron 3 (~3.7 kb downstream of the longest known ARNT mRNA); this may negatively impact CTSK transcript levels by interfering with CTSK expression. Novel CTSK transcripts with alternate 5' splicing and a cryptic upstream promoter were also identified.","method":"RT-PCR spanning ARNT-CTSK intergenic region, quantitative RT-PCR from multiple tissues, EST sequence analysis","journal":"Comparative and functional genomics","confidence":"Medium","confidence_rationale":"Tier 2-3 — direct RT-PCR evidence for read-through transcription; functional consequence (interference with CTSK expression) is inferred rather than experimentally proven","pmids":["18629217"],"is_preprint":false},{"year":2007,"finding":"Nine novel CTSK mutations causing pycnodysostosis were characterized; the L7P mutation in the signal peptide significantly reduces protein expression, indicating the signal peptide is required for targeting and translocation of cathepsin K across the ER membrane. Other missense mutations were predicted by 3D structural modeling to cause incorrect protein folding.","method":"Sanger sequencing, Western blot of COS-7 cells transfected with mutant CTSK cDNAs, 3D structural modeling","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 — direct expression assay in transfected cells linking specific mutation to loss of ER translocation","pmids":["17397052"],"is_preprint":false},{"year":2009,"finding":"Cathepsin K is expressed by translocation renal cell carcinomas bearing TFE3 or TFEB translocations; overexpression of TFEB (or related TFE family members including MITF) drives cathepsin K expression, identifying CTSK as a transcriptional target of the MiTF/TFE transcription factor family.","method":"Immunohistochemistry of cytogenetically confirmed translocation RCCs and control renal neoplasms (n=210+ cases)","journal":"Modern pathology","confidence":"Medium","confidence_rationale":"Tier 3 — IHC-based localization linking TFE family overexpression to cathepsin K expression; no direct transcriptional assay","pmids":["19396149"],"is_preprint":false},{"year":2012,"finding":"Ctsk knockout mice show delayed osteoarthritic progression in a joint destabilization model; CTK-positive chondrocytes and synovial cells are identified as sources of cathepsin K driving OA, and loss of cathepsin K reduces expression of MMP-13 and ADAMTS-5 in chondrocytes.","method":"Ctsk-/- mouse model, destabilization of medial meniscus surgery, histologic scoring (modified Mankin), immunohistochemistry for CTK, MMP-13, ADAMTS-5, TRAP","journal":"Arthritis and rheumatism","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with defined OA phenotype and molecular pathway readout (downstream protease expression)","pmids":["21968827"],"is_preprint":false},{"year":2014,"finding":"Structural basis for cathepsin K collagen fiber degradation was established: cathepsin K forms elongated C-shaped protein dimers that constitute the collagenolytically active unit; glycosaminoglycans bridge the dimer and provide a putative collagen-binding interface. Residues Q21 and Q92 (outside the active site) participate in collagen unfolding; mutations at these sites or perturbation of the dimer interface abolish fiber degradation without affecting gelatin or peptide hydrolysis. Cathepsin K binds specifically at the fibrillar gap region of collagen fibers.","method":"Crystal structure of cathepsin K dimer, molecular modeling of collagen binding, site-directed mutagenesis of Q21/Q92 and dimer interface, scanning electron microscopy of fiber binding, Edman degradation to identify cleavage sites","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — crystal structure combined with mutagenesis, SEM, and Edman degradation in a single study; mechanistically definitive","pmids":["25422423"],"is_preprint":false},{"year":2015,"finding":"Novel compound heterozygous CTSK mutations (p.W29X and p.Y283C) cause pycnodysostosis with dental abnormalities including thickened, softened cementum; the Y283C mutation does not affect mRNA or protein levels but significantly reduces CTSK enzyme activity, and structural modeling shows Y283C disrupts the hydrogen network affecting enzyme self-cleavage/activation.","method":"Histology, atomic force microscopy, micro-CT, in vitro enzyme activity assay in COS-7 cells overexpressing mutant CTSK, 3D structural modeling","journal":"Journal of dental research","confidence":"Medium","confidence_rationale":"Tier 2 — direct enzyme activity measurement of mutant vs wild-type in expression system; single study","pmids":["25731711"],"is_preprint":false},{"year":2018,"finding":"Ctsk-/- mice show delayed OA progression with reduced chondroclast numbers in the growth plate relative to WT; differential gene expression in laser-captured osteoclasts and chondroclasts from Ctsk-/- mice revealed altered expression of Atp6v0d2, Tnfrsf11a, Ca2, Calcr, Ccr1, Gpr68, Itgb3, Nfatc1, and Syk, suggesting cathepsin K differentially regulates chondroclastogenesis.","method":"Ctsk-/- mouse model, DMM surgery, laser capture microdissection, targeted PCR arrays, histomorphometry","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 — KO mouse with laser-captured cell-specific gene expression; single study","pmids":["29781506"],"is_preprint":false},{"year":2019,"finding":"Cathepsin K (Ctsk) regulates TLR9 signaling and autophagy in the context of periodontitis with rheumatoid arthritis; inhibition of Ctsk in vivo (via AAV or BML-244) reduces TLR9, TFEB, LC3, macrophage infiltration, and inflammatory cytokines in periodontal lesions; in vitro, Ctsk inhibition specifically suppresses TLR9-downstream signaling proteins and autophagy-related proteins in macrophages.","method":"DBA/J1 mouse model, AAV-mediated Ctsk knockdown, BML-244 inhibitor, Western blot, IHC, qRT-PCR, IF, siRNA in macrophages, CpG ODN stimulation","journal":"Cell proliferation / Journal of clinical periodontology","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo genetic/pharmacological inhibition with mechanistic pathway analysis in vitro; two independent publications","pmids":["31737959","30636333"],"is_preprint":false},{"year":2020,"finding":"RUNX2 promotes osteoclast differentiation and bone resorption through the AKT/NFATc1/CTSK axis: wild-type RUNX2 increases mTORC2 activity and specifically promotes AKT phosphorylation at Ser473, which enhances NFATc1 nuclear translocation and increases CTSK expression; AKT inhibition abolishes this, and constitutively active AKT rescues osteoclastogenesis in mutant cells.","method":"Stable RAW264.7 cell lines expressing WT or mutant RUNX2, F-actin ring formation assay, bone resorption pit assay, mTORC2/AKT inhibition, NFATc1 nuclear translocation assay, Western blot","journal":"Calcified tissue international","confidence":"Medium","confidence_rationale":"Tier 2 — pathway epistasis with genetic rescue experiment; single lab but multiple orthogonal methods","pmids":["32008052"],"is_preprint":false},{"year":2022,"finding":"CTSK mediates castration-resistant prostate cancer (CRPC) growth and metastasis via the IL-17 signaling/CTSK/EMT axis; CTSK promotes EMT to drive metastasis and proliferation, and CTSK expression is linked to M2 macrophage polarization, forming a feedback circuit between M2 TAMs and CRPC tissue.","method":"In vivo and in vitro experiments in CRPC cells, gene knockdown/overexpression, IL-17 pathway manipulation, M2 macrophage co-culture, EMT marker analysis","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — multiple in vitro/in vivo assays; single lab","pmids":["36138018"],"is_preprint":false},{"year":2022,"finding":"Loss of Trp53 and Rb1 in Ctsk-expressing cells drives osteosarcoma via YAP activation; YAP/TEAD1 complex binds the Glut1 promoter to upregulate glucose transporter expression, leading to overactive glucose metabolism; ablation of YAP signaling inhibits energy metabolism and delays osteosarcoma progression in Ctsk-Cre;Trp53f/f/Rb1f/f mice.","method":"Conditional KO mouse model (Ctsk-Cre;Trp53f/f/Rb1f/f), mechanistic studies of YAP expression/activity, promoter luciferase for Glut1, YAP inhibition","journal":"MedComm","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo genetic model with mechanistic promoter assay; single lab","pmids":["35615117"],"is_preprint":false},{"year":2023,"finding":"Sfrp4 is required for maintenance of Ctsk-lineage periosteal stem cells (PSCs); Sfrp4 deletion reduces the PSC pool, impairs clonal multipotency for osteoblast/chondrocyte differentiation, and abolishes the PTH-dependent increase in PSC numbers and cortical bone formation; Sfrp4 regulates Ctsk-lineage PSCs by maintaining Wnt signaling and Hh pathway-associated genes.","method":"Sfrp4 global deletion mouse model, Ctsk-lineage tracing, clonal multipotency assays, bulk RNA sequencing of Ctsk-lineage PSCs, PTH treatment, periosteal injury model","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 — genetic deletion with lineage tracing, RNA-seq, and functional rescue; single study","pmids":["37931101"],"is_preprint":false},{"year":2024,"finding":"METTL3-mediated m6A modification regulates Ctsk expression in calvarial Ctsk+ stem cells; loss of Mettl3 in Ctsk+ lineage cells reduces Hedgehog (Hh) signaling, delays suture formation, and impairs calvarial bone formation; restoration of Hh signaling partially rescues these defects.","method":"Conditional Mettl3 KO in Ctsk-Cre mice, MeRIP-seq plus RNA-seq, micro-CT, histology, Sufu allele crossing for Hh restoration, SAG21 local administration","journal":"Journal of dental research","confidence":"Medium","confidence_rationale":"Tier 2 — conditional KO with m6A sequencing and genetic rescue; single study","pmids":["38752256"],"is_preprint":false},{"year":2024,"finding":"T-2 toxin induces cartilage ECM degradation by downregulating METTL3-mediated m6A methylation of Ctsk mRNA; METTL3 silencing exacerbates HT-2 toxin-induced ECM degradation, while Ctsk silencing also aggravates it, suggesting Ctsk normally has a protective role in cartilage maintenance; dietary methionine supplementation increases m6A levels in vivo and mitigates cartilage damage.","method":"MeRIP-seq, RNA-seq, siRNA knockdown of METTL3 and Ctsk in chondrocytes, in vivo methionine supplementation","journal":"International immunopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — m6A sequencing combined with knockdown and in vivo rescue; single study","pmids":["39426235"],"is_preprint":false},{"year":2025,"finding":"Loss of CTSK in trabecular meshwork (TM) cells disrupts collagen biogenesis and ECM homeostasis; siRNA knockdown of CTSK increases intracellular calcium, activates PRKD1 which drives LIMK1/SSH1/cofilin-mediated actin polymerization and focal adhesion maturation, and downregulates RhoQ and myosin motor proteins, indicating altered mechanotransduction; apoptotic markers increase without caspase 3/7 activation, suggesting apoptosis-independent remodeling.","method":"siRNA-mediated CTSK knockdown in human TM cells, unbiased proteomics (mass spectrometry), intracellular calcium measurement, actin/focal adhesion imaging","journal":"bioRxiv (preprint)","confidence":"Medium","confidence_rationale":"Tier 2 — unbiased proteomics plus functional assays; preprint, single study","pmids":["bio_10.1101_2025.02.10.637394"],"is_preprint":true},{"year":2025,"finding":"HIF-1α in Ctsk+ osteoclasts regulates lysosomal biogenesis via the TSC2-mTORC1-TFEB axis; conditional HIF-1α knockout in Ctsk+ cells causes disorganized ruffled borders, defective lysosomal biogenesis, and abnormal condylar morphogenesis with calcified cartilage accumulation and impaired subchondral bone formation.","method":"DTR transgenic and conditional HIF-1α knockout (HIF-1α∆ctsk-cre) mouse models, histology, micro-CT, cellular ultrastructure analysis, gene expression","journal":"Journal of dental research","confidence":"Medium","confidence_rationale":"Tier 2 — conditional KO with defined cellular phenotype and pathway identification; single study","pmids":["41108121"],"is_preprint":false},{"year":2025,"finding":"Sgk1 regulates osteoclastogenesis via Stat3 phosphorylation at Tyr705, leading to Mycl upregulation; Mycl directly binds the Ctsk promoter and drives Ctsk transcription; Mycl overexpression rescues osteoclast differentiation impaired by Sgk1 inhibition, defining a Sgk1-Stat3-Mycl-Ctsk signaling axis.","method":"Sgk1 inhibitor (GSK650394), Mycl overexpression rescue in osteoclasts, Ctsk promoter binding assay, in vivo micro-CT in Sgk1 inhibitor-treated mice","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — genetic rescue experiment with promoter binding evidence and in vivo validation; single study","pmids":["41266497"],"is_preprint":false},{"year":2025,"finding":"Tucatinib directly binds and inhibits CTSK enzymatic activity (confirmed by microscale thermophoresis and CTSK activity assays); it also suppresses NFATc1-driven osteoclast differentiation by inhibiting DRP1 phosphorylation at Ser616, reducing mitochondrial ROS and stabilizing mitochondrial dynamics, thereby defining a DRP1/NFATc1/CTSK axis in osteoclastogenesis.","method":"Virtual screening, microscale thermophoresis, CTSK activity assays, DRP1 phosphorylation assay, mtROS measurement, ovariectomized mouse model","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 1-2 — direct binding confirmed by biophysical assay plus enzyme activity and in vivo validation; single study","pmids":["41974330"],"is_preprint":false},{"year":2025,"finding":"Liquiritin enhances CTSK-mediated lysosomal degradation of CXCL1 in tumor-associated macrophages (TAMs); liquiritin accumulates in TAM lysosomes, increases CXCL1 and lysosome colocalization, and upregulates CTSK expression to accelerate CXCL1 degradation, thereby suppressing CXCL1-driven breast cancer neoangiogenesis.","method":"TAM membrane-capture/LC-MS screening, CXCL1 ELISA, lysosome/CXCL1 colocalization assay, CTSK expression measurement, in vivo breast cancer xenograft and zebrafish models","journal":"Phytomedicine","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic colocalization and functional rescue with in vivo validation; single lab","pmids":["41072283"],"is_preprint":false},{"year":2013,"finding":"Caffeine directly enhances osteoclast differentiation and maturation by activating p38 MAP kinase, which induces Mitf expression and transcriptional upregulation of DC-STAMP (cell fusion), and ultimately increases cathepsin K (CtsK) and TRAP expression; the p38 inhibitor SB203580 blocks caffeine-induced CtsK upregulation.","method":"TRAP staining of osteoclasts, p38 inhibitor, real-time PCR, luciferase reporter for DC-STAMP","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2-3 — pharmacological pathway dissection with reporter assay; places CTSK downstream of p38/Mitf in osteoclast maturation","pmids":["23434822"],"is_preprint":false},{"year":2003,"finding":"Cathepsin K is expressed by prostate cancer cells and is enzymatically active (collagenase and fluorogenic peptide activity); cathepsin K mRNA and protein are present in prostate cancer cell lines and primary tumors, with significantly higher expression in bone metastases than primary cancer, and serum NTx (a cathepsin K-mediated bone resorption marker) is elevated in patients with bone metastases.","method":"RT-PCR, in situ hybridization, immunohistochemistry, Western blot after immunoprecipitation, fluorogenic enzyme activity assay, type I collagen degradation assay","journal":"Journal of bone and mineral research","confidence":"Medium","confidence_rationale":"Tier 2 — direct enzymatic activity confirmed in cancer cell lines; single study","pmids":["12568399"],"is_preprint":false}],"current_model":"Cathepsin K (CTSK) is a lysosomal cysteine protease of the papain superfamily, highly expressed in osteoclasts (localizing to the ruffled border during active resorption), that degrades type I collagen, osteopontin, aggrecan, and other ECM proteins; its unique and potent collagenase activity requires oligomeric complex formation with chondroitin sulfate glycosaminoglycans (5:5 stoichiometry) facilitated by a dimer interface involving residues Q21/Q92, while monomeric enzyme retains only gelatinase activity; CTSK transcription during osteoclastogenesis is cooperatively regulated by RANKL-induced p38 MAP kinase phosphorylation of NFATc1, which complexes with PU.1 and MITF at the CTSK promoter, and is also driven by an Sgk1-Stat3-Mycl axis; CTSK is inhibited by SCCA1 serpin via stable 1:1 complex formation; loss-of-function mutations in CTSK cause pycnodysostosis by eliminating collagenolytic activity in osteoclasts; beyond bone, CTSK is active in synovial fibroblasts driving RA cartilage destruction, in lung fibroblasts maintaining ECM homeostasis, in CTSK+ periosteal stem cells regulated by Sfrp4/Wnt and METTL3/Hedgehog signaling, and in tumor-associated macrophages where it mediates lysosomal degradation of CXCL1 to modulate angiogenesis."},"narrative":{"teleology":[{"year":1995,"claim":"Molecular cloning of cathepsin K established it as a novel papain-family cysteine proteinase with predominant osteoclast expression, answering the question of which protease mediates osteoclastic bone matrix degradation.","evidence":"cDNA library screening with rabbit OC-2 probe, Northern blot tissue distribution in human tissues and osteoclastomas","pmids":["7818555","7576232","7805878"],"confidence":"High","gaps":["Substrate specificity not yet defined","No in vivo loss-of-function evidence","Mechanism of activation unknown"]},{"year":1996,"claim":"Identification of CTSK mutations as the cause of pycnodysostosis, combined with in vitro demonstration of collagenolytic and osteonectin-degrading activity, linked cathepsin K enzymatic function directly to human skeletal disease and defined its key substrates.","evidence":"Genetic linkage and Sanger sequencing in pycnodysostosis families; baculovirus-expressed recombinant cathepsin K tested on type I collagen, osteonectin, and fluorogenic peptides with inhibitor profiling","pmids":["8703060","8647860"],"confidence":"High","gaps":["Mechanism of collagen triple-helix cleavage unknown","No crystal structure yet","Quantitative genotype–phenotype relationship not established"]},{"year":1997,"claim":"The crystal structure of cathepsin K complexed with an inhibitor revealed the active-site architecture, and immunolocalization placed cathepsin K at the osteoclast ruffled border during active resorption, linking structural knowledge to the subcellular site of bone degradation.","evidence":"X-ray crystallography of inhibitor-bound cathepsin K; immunohistochemistry and in situ hybridization on bone and giant cell tumor sections","pmids":["9033587","9028530"],"confidence":"High","gaps":["How cathepsin K achieves collagenase versus gelatinase selectivity is unknown","No information on cofactor requirements","Genomic regulation largely unexplored"]},{"year":1998,"claim":"Discovery that the serpin SCCA1 forms a stable 1:1 inhibitory complex with cathepsin K with rapid kinetics identified the first endogenous cross-class inhibitor, establishing a regulatory mechanism for controlling cathepsin K activity.","evidence":"Kinetic analysis with second-order rate constants, stoichiometry measurement, SDS-PAGE detection of stable complex","pmids":["9548757"],"confidence":"High","gaps":["Physiological relevance of SCCA1 inhibition in bone or other tissues not shown","Other endogenous inhibitors not surveyed","In vivo consequence of disrupting this interaction unknown"]},{"year":2002,"claim":"The requirement for chondroitin sulfate GAG complex formation (5:5 oligomer) for collagenase activity, versus monomeric gelatinase activity, resolved why the Y212C pycnodysostosis mutant retains gelatinase but not collagenase function, fundamentally distinguishing cathepsin K from other cysteine cathepsins.","evidence":"In vitro complex formation, collagen and gelatin degradation assays, analysis of Y212C pycnodysostosis mutant","pmids":["12039963","14645229"],"confidence":"High","gaps":["Structural basis of the oligomeric complex not yet visualized","Identity of GAG-binding residues not mapped","Whether other GAGs serve as cofactors in non-bone tissues unknown"]},{"year":2004,"claim":"RANKL-induced transcriptional regulation of CTSK was dissected: p38 MAPK phosphorylates NFATc1, which complexes with PU.1 and MITF at the CTSK promoter, explaining how osteoclast differentiation signals converge to activate this effector protease gene.","evidence":"Cathepsin K promoter deletion reporter assays, overexpression in RAW264 cells, p38 inhibitor SB203580, nuclear localization studies","pmids":["15304486"],"confidence":"High","gaps":["Chromatin accessibility and epigenetic regulation at the CTSK locus not examined","Relative contribution of each transcription factor not quantified","Whether this promoter logic applies in non-osteoclast cell types is unknown"]},{"year":2004,"claim":"Demonstration that CTSK-knockout mice develop exacerbated lung fibrosis after bleomycin challenge, with reduced fibroblast collagenolytic activity, established cathepsin K as a homeostatic protease in extracellular matrix turnover beyond bone.","evidence":"Bleomycin-induced fibrosis in Ctsk−/− mice, primary lung fibroblast collagenolytic assays","pmids":["15161653"],"confidence":"High","gaps":["Whether cathepsin K acts intracellularly or extracellularly in lung fibroblasts unclear","Specific collagen substrates in lung not identified","Compensation by other cathepsins not assessed"]},{"year":2014,"claim":"Structural resolution of the collagenolytically active cathepsin K dimer bridged by GAGs, with mutagenesis proving that Q21 and Q92 mediate collagen unfolding while the dimer interface is essential for fibrillar degradation, provided a complete structural mechanism for collagenolysis distinct from MMP-type collagenases.","evidence":"Crystal structure of cathepsin K dimer, site-directed mutagenesis of Q21/Q92 and dimer interface, SEM of collagen fiber binding, Edman degradation of cleavage sites","pmids":["25422423"],"confidence":"High","gaps":["Full atomic model of the cathepsin K–GAG–collagen ternary complex not available","Dynamics of dimer assembly on the collagen fiber in vivo unknown","Whether the dimer mechanism applies to non-type-I collagens not tested"]},{"year":2012,"claim":"Ctsk-knockout mice showed delayed osteoarthritis progression with reduced MMP-13 and ADAMTS-5 expression, revealing that cathepsin K not only directly degrades cartilage matrix but also cross-regulates other cartilage-degrading proteases, amplifying joint destruction.","evidence":"Ctsk−/− mouse DMM OA model, histologic scoring, IHC for MMP-13/ADAMTS-5","pmids":["21968827"],"confidence":"High","gaps":["Whether cathepsin K regulates MMP-13/ADAMTS-5 transcriptionally or post-translationally unknown","Human OA validation lacking","Relative contribution of osteoclasts versus chondrocytes not resolved"]},{"year":2025,"claim":"An Sgk1–Stat3–Mycl transcriptional axis was identified as a parallel pathway to NFATc1 for driving CTSK expression during osteoclastogenesis, with Mycl directly binding the CTSK promoter and rescuing differentiation impaired by Sgk1 inhibition.","evidence":"Sgk1 inhibitor (GSK650394), Mycl overexpression rescue, Ctsk promoter binding assay, in vivo micro-CT","pmids":["41266497"],"confidence":"Medium","gaps":["Relative contribution of Mycl versus NFATc1 at the endogenous CTSK promoter not quantified","ChIP-seq confirmation of Mycl occupancy lacking","Single lab with single inhibitor"]},{"year":2025,"claim":"Cathepsin K was shown to mediate lysosomal degradation of CXCL1 in tumor-associated macrophages, suppressing CXCL1-driven neoangiogenesis, extending cathepsin K's functional roles into immune–tumor microenvironment regulation.","evidence":"CXCL1–lysosome colocalization, CTSK expression modulation, breast cancer xenograft and zebrafish angiogenesis models","pmids":["41072283"],"confidence":"Medium","gaps":["Whether CXCL1 is a direct cathepsin K substrate or degraded via secondary lysosomal proteases not distinguished","Generalizability to other tumor types untested","Single study"]},{"year":null,"claim":"Key unresolved questions include the atomic structure of the cathepsin K–GAG–collagen ternary complex, the in vivo relevance of SCCA1 inhibition, the mechanistic basis for cathepsin K's regulation of downstream proteases (MMP-13, ADAMTS-5), and the full scope of cathepsin K substrates and functions in non-bone tissues such as the tumor microenvironment.","evidence":"","pmids":[],"confidence":"High","gaps":["No ternary complex structure","SCCA1 inhibition not validated in vivo","Substrate repertoire beyond collagen I and aggrecan incompletely catalogued"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[2,9,10,11,19]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[2,9,10,11,12]}],"localization":[{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[5,30,33]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[5,10,14]}],"pathway":[{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[2,9,10,11,14,19]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[2,6,11,16]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,8,18,24,35]}],"complexes":["Cathepsin K–chondroitin sulfate pentameric complex"],"partners":["SCCA1","NFATC1","PU.1","MITF","MYCL","TFEB"],"other_free_text":[]},"mechanistic_narrative":"Cathepsin K is a lysosomal cysteine protease of the papain superfamily that serves as the principal collagenase in osteoclast-mediated bone resorption and a key regulator of extracellular matrix turnover in multiple tissues. Its unique collagenolytic activity requires oligomerization with chondroitin sulfate glycosaminoglycans into a pentameric complex (5:5 stoichiometry), in which C-shaped dimers bridged by GAGs bind collagen fibrils at the gap region and unfold triple-helical collagen via residues Q21 and Q92; monomeric cathepsin K retains only gelatinase activity [PMID:12039963, PMID:25422423, PMID:14645229]. Loss-of-function mutations in CTSK cause pycnodysostosis, an autosomal recessive osteosclerosis, by abolishing osteoclastic collagen degradation [PMID:8703060]. CTSK transcription during osteoclastogenesis is cooperatively driven by RANKL-induced p38/NFATc1 signaling in concert with PU.1 and MITF, and by an Sgk1–Stat3–Mycl axis, while beyond bone CTSK maintains ECM homeostasis in lung and synovial fibroblasts and mediates lysosomal degradation of CXCL1 in tumor-associated macrophages to modulate angiogenesis [PMID:15304486, PMID:41266497, PMID:15161653, PMID:11733367, PMID:41072283]."},"prefetch_data":{"uniprot":{"accession":"P43235","full_name":"Cathepsin K","aliases":["Cathepsin O","Cathepsin O2","Cathepsin X"],"length_aa":329,"mass_kda":37.0,"function":"Thiol protease involved in osteoclastic bone resorption and may participate partially in the disorder of bone remodeling. Displays potent endoprotease activity against fibrinogen at acid pH. May play an important role in extracellular matrix degradation. Involved in the release of thyroid hormone thyroxine (T4) by limited proteolysis of TG/thyroglobulin in the thyroid follicle lumen (PubMed:11082042)","subcellular_location":"Lysosome; Secreted; Apical cell membrane","url":"https://www.uniprot.org/uniprotkb/P43235/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CTSK","classification":"Not Classified","n_dependent_lines":20,"n_total_lines":1208,"dependency_fraction":0.016556291390728478},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CTSK","total_profiled":1310},"omim":[{"mim_id":"607948","title":"MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/607948"},{"mim_id":"605474","title":"TOLL-LIKE RECEPTOR 9; TLR9","url":"https://www.omim.org/entry/605474"},{"mim_id":"604312","title":"CYSTATIN 3; CST3","url":"https://www.omim.org/entry/604312"},{"mim_id":"604146","title":"SYNAPTOTAGMIN 7; SYT7","url":"https://www.omim.org/entry/604146"},{"mim_id":"601105","title":"CATHEPSIN K; CTSK","url":"https://www.omim.org/entry/601105"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Vesicles","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"cervix","ntpm":333.6}],"url":"https://www.proteinatlas.org/search/CTSK"},"hgnc":{"alias_symbol":["PKND"],"prev_symbol":["CTSO2","CTSO","PYCD"]},"alphafold":{"accession":"P43235","domains":[{"cath_id":"3.90.70.10","chopping":"84-329","consensus_level":"medium","plddt":96.8463,"start":84,"end":329}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P43235","model_url":"https://alphafold.ebi.ac.uk/files/AF-P43235-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P43235-F1-predicted_aligned_error_v6.png","plddt_mean":94.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CTSK","jax_strain_url":"https://www.jax.org/strain/search?query=CTSK"},"sequence":{"accession":"P43235","fasta_url":"https://rest.uniprot.org/uniprotkb/P43235.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P43235/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P43235"}},"corpus_meta":[{"pmid":"15987910","id":"PMC_15987910","title":"Mycobacterium tuberculosis serine/threonine kinases PknB, PknD, PknE, and PknF phosphorylate multiple FHA domains.","date":"2005","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/15987910","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36138018","id":"PMC_36138018","title":"Cathepsin K regulates the tumor growth and metastasis by IL-17/CTSK/EMT axis and mediates M2 macrophage polarization in castration-resistant prostate cancer.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36138018","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22243650","id":"PMC_22243650","title":"Role of Mycobacterium tuberculosis pknD in the pathogenesis of central nervous system tuberculosis.","date":"2012","source":"BMC microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/22243650","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16879801","id":"PMC_16879801","title":"Mycobacterium tuberculosis transporter MmpL7 is a potential substrate for kinase PknD.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16879801","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17397052","id":"PMC_17397052","title":"Molecular analysis and characterization of nine novel CTSK mutations in twelve patients affected by pycnodysostosis. Mutation in brief #961. Online.","date":"2007","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/17397052","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15136047","id":"PMC_15136047","title":"Sensor domain of the Mycobacterium tuberculosis receptor Ser/Thr protein kinase, PknD, forms a highly symmetric beta propeller.","date":"2004","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15136047","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23434822","id":"PMC_23434822","title":"Caffeine enhances osteoclast differentiation and maturation through p38 MAP kinase/Mitf and DC-STAMP/CtsK and TRAP pathway.","date":"2013","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/23434822","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21968827","id":"PMC_21968827","title":"Osteoarthritic change is delayed in a Ctsk-knockout mouse model of osteoarthritis.","date":"2012","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/21968827","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17242402","id":"PMC_17242402","title":"Allosteric activation by dimerization of the PknD receptor Ser/Thr protein kinase from Mycobacterium tuberculosis.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17242402","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31737959","id":"PMC_31737959","title":"Inhibition of Ctsk modulates periodontitis with arthritis via downregulation of TLR9 and autophagy.","date":"2019","source":"Cell proliferation","url":"https://pubmed.ncbi.nlm.nih.gov/31737959","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10491211","id":"PMC_10491211","title":"Mutations of CTSK result in pycnodysostosis via a reduction in cathepsin K protein.","date":"1999","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/10491211","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9143491","id":"PMC_9143491","title":"Genomic organization and chromosome localization of the human cathepsin K gene (CTSK).","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9143491","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30636333","id":"PMC_30636333","title":"Inhibition of Ctsk alleviates periodontitis and comorbid rheumatoid arthritis via downregulation of the TLR9 signalling pathway.","date":"2019","source":"Journal of clinical periodontology","url":"https://pubmed.ncbi.nlm.nih.gov/30636333","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17766419","id":"PMC_17766419","title":"Chlamydophila pneumoniae PknD exhibits dual amino acid specificity and phosphorylates Cpn0712, a putative type III secretion YscD homolog.","date":"2007","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/17766419","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9613569","id":"PMC_9613569","title":"Cloning and characterisation of the pknD gene encoding an eukaryotic-type protein kinase in the cyanobacterium Anabaena sp. PCC7120.","date":"1998","source":"Molecular & general genetics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/9613569","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32008052","id":"PMC_32008052","title":"New Function of RUNX2 in Regulating Osteoclast Differentiation via the AKT/NFATc1/CTSK Axis.","date":"2020","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/32008052","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30387921","id":"PMC_30387921","title":"LncRNA-Jak3:Jak3 coexpressed pattern regulates monosodium urate crystal-induced osteoclast differentiation through Nfatc1/Ctsk expression.","date":"2018","source":"Environmental toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/30387921","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25731711","id":"PMC_25731711","title":"Dental Abnormalities Caused by Novel Compound Heterozygous CTSK Mutations.","date":"2015","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/25731711","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28968398","id":"PMC_28968398","title":"SNPs near the cysteine proteinase cathepsin O gene (CTSO) determine tamoxifen sensitivity in ERα-positive breast cancer through regulation of BRCA1.","date":"2017","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28968398","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24269275","id":"PMC_24269275","title":"Exome sequencing identifies CTSK mutations in patients originally diagnosed as intermediate osteopetrosis.","date":"2013","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/24269275","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20933472","id":"PMC_20933472","title":"Effect of PstS sub-units or PknD deficiency on the survival of Mycobacterium tuberculosis.","date":"2010","source":"Tuberculosis (Edinburgh, Scotland)","url":"https://pubmed.ncbi.nlm.nih.gov/20933472","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10913696","id":"PMC_10913696","title":"The Mycobacterium bovis homologous protein of the Mycobacterium tuberculosis serine/threonine protein kinase Mbk (PknD) is truncated.","date":"2000","source":"FEMS microbiology letters","url":"https://pubmed.ncbi.nlm.nih.gov/10913696","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16739134","id":"PMC_16739134","title":"Characterization of the phosphorylation sites of Mycobacterium tuberculosis serine/threonine protein kinases, PknA, PknD, PknE, and PknH by mass spectrometry.","date":"2006","source":"Proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/16739134","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19662513","id":"PMC_19662513","title":"A single nucleotide polymorphism in the porcine cathepsin K (CTSK) gene is associated with back fat thickness and production traits in Italian Duroc pigs.","date":"2009","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/19662513","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27558267","id":"PMC_27558267","title":"Molecular analysis of the CTSK gene in a cohort of 33 Brazilian families with pycnodysostosis from a cluster in a Brazilian Northeast region.","date":"2016","source":"European journal of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/27558267","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19674475","id":"PMC_19674475","title":"A mutation in CTSK gene in an autosomal recessive pycnodysostosis family of Pakistani origin.","date":"2009","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19674475","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29781506","id":"PMC_29781506","title":"Articular cartilage protection in Ctsk-/- mice is associated with cellular and molecular changes in subchondral bone and cartilage matrix.","date":"2018","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29781506","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9790772","id":"PMC_9790772","title":"Genomic structure and chromosomal localization of the human cathepsin O gene (CTSO).","date":"1998","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9790772","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35615117","id":"PMC_35615117","title":"Deletion of Trp53 and Rb1 in Ctsk-expressing cells drives osteosarcoma progression by activating glucose metabolism and YAP signaling.","date":"2022","source":"MedComm","url":"https://pubmed.ncbi.nlm.nih.gov/35615117","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35456040","id":"PMC_35456040","title":"Verteporfin Inhibits the Progression of Spontaneous Osteosarcoma Caused by Trp53 and Rb1 Deficiency in Ctsk-Expressing Cells via Impeding Hippo Pathway.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35456040","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29796728","id":"PMC_29796728","title":"Genetic study of eight Egyptian patients with pycnodysostosis: identification of novel CTSK mutations and founder effect.","date":"2018","source":"Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA","url":"https://pubmed.ncbi.nlm.nih.gov/29796728","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39667460","id":"PMC_39667460","title":"Identification of core immune-related genes CTSK, C3, and IFITM1 for diagnosing Helicobacter pylori infection-associated gastric cancer through transcriptomic analysis.","date":"2024","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/39667460","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23776655","id":"PMC_23776655","title":"Vaccination with recombinant Mycobacterium tuberculosis PknD attenuates bacterial dissemination to the brain in guinea pigs.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23776655","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19828035","id":"PMC_19828035","title":"A novel inhibitor of Chlamydophila pneumoniae protein kinase D (PknD) inhibits phosphorylation of CdsD and suppresses bacterial replication.","date":"2009","source":"BMC microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/19828035","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32117071","id":"PMC_32117071","title":"Associations of Serum Cathepsin K and Polymorphisms in CTSK Gene With Bone Mineral Density and Bone Metabolism Markers in Postmenopausal Chinese Women.","date":"2020","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32117071","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25725806","id":"PMC_25725806","title":"A Mutation in CTSK Gene in an Autosomal Recessive Pycnodysostosis Family of Chinese Origin.","date":"2015","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/25725806","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28856246","id":"PMC_28856246","title":"Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes.","date":"2017","source":"NPJ breast cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28856246","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37931101","id":"PMC_37931101","title":"Sfrp4 is required to maintain Ctsk-lineage periosteal stem cell niche function.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/37931101","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20305575","id":"PMC_20305575","title":"A novel missense mutation in cathepsin K (CTSK) gene in a consanguineous Pakistani family with pycnodysostosis.","date":"2010","source":"Journal of investigative medicine : the official publication of the American Federation for Clinical Research","url":"https://pubmed.ncbi.nlm.nih.gov/20305575","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25410008","id":"PMC_25410008","title":"CTSK inhibitor exert its anti-obesity effects through regulating adipocyte differentiation in high-fat diet induced obese mice.","date":"2014","source":"Endocrine journal","url":"https://pubmed.ncbi.nlm.nih.gov/25410008","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21099701","id":"PMC_21099701","title":"Familial pycnodysostosis: identification of a novel mutation in the CTSK gene (cathepsin K).","date":"2011","source":"Journal of investigative medicine : the official publication of the American Federation for Clinical Research","url":"https://pubmed.ncbi.nlm.nih.gov/21099701","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10372556","id":"PMC_10372556","title":"Complete genomic structure of the mouse cathepsin K gene (Ctsk) and its localization next to the Arnt gene on mouse chromosome 3.","date":"1999","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/10372556","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32224503","id":"PMC_32224503","title":"Inverse relationship between autophagy and CTSK is related to bovine embryo quality.","date":"2020","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/32224503","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33945887","id":"PMC_33945887","title":"Phenotypic and genotypic spectrum of CTSK variants in a cohort of twenty-five Indian patients with pycnodysostosis.","date":"2021","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33945887","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24134756","id":"PMC_24134756","title":"Novel CTSK mutation resulting in an entire exon 2 skipping in a Thai girl with pycnodysostosis.","date":"2013","source":"Pediatrics international : official journal of the Japan Pediatric Society","url":"https://pubmed.ncbi.nlm.nih.gov/24134756","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38752256","id":"PMC_38752256","title":"METTL3 Modulates Ctsk+ Lineage Supporting Cranial Osteogenesis via Hedgehog.","date":"2024","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/38752256","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27400912","id":"PMC_27400912","title":"Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials.","date":"2016","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/27400912","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39426235","id":"PMC_39426235","title":"T-2 toxin induces chondrocyte extracellular matrix degradation by regulating the METTL3-mediated Ctsk m6A modification.","date":"2024","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39426235","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36245435","id":"PMC_36245435","title":"Altering osteoclast numbers using CTSK models in utero affects mice offspring craniofacial morphology.","date":"2022","source":"Orthodontics & craniofacial research","url":"https://pubmed.ncbi.nlm.nih.gov/36245435","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39424989","id":"PMC_39424989","title":"IL-17RA/CTSK axis mediates H. pylori-induced castration-resistant prostate cancer growth.","date":"2024","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/39424989","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37930479","id":"PMC_37930479","title":"Prediction and therapeutic targeting of the tumor microenvironment-associated gene CTSK in gastric cancer.","date":"2023","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37930479","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29441215","id":"PMC_29441215","title":"Pycnodysostosis: Novel Variants in CTSK and Occurrence of Giant Cell Tumor.","date":"2017","source":"Journal of pediatric genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29441215","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35315254","id":"PMC_35315254","title":"Clinical and genetic characterization of three Russian patients with pycnodysostosis due to pathogenic variants in the CTSK gene.","date":"2022","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35315254","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37639249","id":"PMC_37639249","title":"Discovery of CTSK+ Periosteal Stem Cells Mediating Bone Repair in Orbital Reconstruction.","date":"2023","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/37639249","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34143773","id":"PMC_34143773","title":"Phlpp1 is induced by estrogen in osteoclasts and its loss in Ctsk-expressing cells does not protect against ovariectomy-induced bone loss.","date":"2021","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/34143773","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30967749","id":"PMC_30967749","title":"A Novel Variant c.847T>C in CTSK Gene Leading to Pycnodysostosis: A Case Report.","date":"2019","source":"Clinical medicine insights. Case reports","url":"https://pubmed.ncbi.nlm.nih.gov/30967749","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38203479","id":"PMC_38203479","title":"Andrographolide Alleviates Oxidative Damage and Inhibits Apoptosis Induced by IHNV Infection via CTSK/BCL2/Cytc Axis.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38203479","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40315697","id":"PMC_40315697","title":"CTSK as a Collagen Degradation Marker Induces Gingival Recession During High-Force Orthodontic Tooth Movement.","date":"2025","source":"International dental journal","url":"https://pubmed.ncbi.nlm.nih.gov/40315697","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39392433","id":"PMC_39392433","title":"Exosomes derived from mucoperiosteum Krt14+Ctsk+ cells promote bone regeneration by coupling enhanced osteogenesis and angiogenesis.","date":"2024","source":"Biomaterials science","url":"https://pubmed.ncbi.nlm.nih.gov/39392433","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37255004","id":"PMC_37255004","title":"Unravelling the Relacatib activity against the CTSK proteins causing pycnodysostosis: a molecular docking and dynamics approach.","date":"2023","source":"Journal of biomolecular structure & dynamics","url":"https://pubmed.ncbi.nlm.nih.gov/37255004","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37920752","id":"PMC_37920752","title":"Association Between CTSK Gene Polymorphisms and Response to Alendronate Treatment in Postmenopausal Chinese Women with Low Bone Mineral Density.","date":"2023","source":"Pharmacogenomics and personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37920752","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40670571","id":"PMC_40670571","title":"Identification of CTSK as a TLR-related critical biomarker in liver cirrhosis via integrative bioinformatics and pathological characterization.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/40670571","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36752216","id":"PMC_36752216","title":"A SNP in the ovine cathepsin K (CTSK) gene is associated with yearling growth performance in a crossbred sheep population.","date":"2023","source":"Animal biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/36752216","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41108121","id":"PMC_41108121","title":"Ctsk+ Osteoclasts Orchestrate Condylar Morphogenesis via Hypoxic Lysosome.","date":"2025","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/41108121","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41065357","id":"PMC_41065357","title":"Cathepsin K (CTSK) in Inflammatory and Immune-Mediated Diseases.","date":"2025","source":"Immunological investigations","url":"https://pubmed.ncbi.nlm.nih.gov/41065357","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18629217","id":"PMC_18629217","title":"Atypical CTSK transcripts and ARNT transcription read-through into CTSK.","date":"2005","source":"Comparative and functional genomics","url":"https://pubmed.ncbi.nlm.nih.gov/18629217","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40792611","id":"PMC_40792611","title":"RANKL, OPG, and CTS-K Release in Bone Response to Immediate Nonfunctional Loading of a Single Implant in Mandibular Molar Sites During Osseointegration Establishment.","date":"2025","source":"Clinical and experimental dental research","url":"https://pubmed.ncbi.nlm.nih.gov/40792611","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41072283","id":"PMC_41072283","title":"Liquiritin in Aiduqing formula inhibits breast cancer neoangiogenesis by suppressing CTSK-mediated lysosomal degradation of CXCL1 in tumor-associated macrophages.","date":"2025","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/41072283","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39684735","id":"PMC_39684735","title":"Case Report: A Novel Homozygous Variant of the CTSK Gene in Rare Pycnodysostosis.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39684735","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41266497","id":"PMC_41266497","title":"Mycl, activated by Sgk1-phosphorylated Stat3, mediates osteoclastogenesis via Ctsk transcriptional regulation.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/41266497","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41974330","id":"PMC_41974330","title":"Tucatinib alleviates postmenopausal osteoporosis by suppressing osteoclast differentiation via regulating the DRP1/NFATc1/CTSK signaling pathway.","date":"2026","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/41974330","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.07.21.665966","title":"Wnt5a gain- and loss-of-function present distinctly in craniofacial bone","date":"2025-07-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.21.665966","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.02.10.637394","title":"Loss of Cathepsin K impairs collagen biogenesis and enhances actin polymerization in trabecular meshwork","date":"2025-02-11","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.10.637394","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.10.03.680228","title":"Zyxin Restricts Viral Fusion and Entry across Multiple Virus Families","date":"2025-10-03","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.03.680228","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.08.31.610656","title":"Osteogenic CpG Oligodeoxynucleotide, iSN40, Inhibits Osteo-clastogenesis in a TLR9-Dependent Manner","date":"2024-09-02","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.31.610656","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.10.02.616263","title":"Early intermittent low-dose sclerostin antibody treatment promotes surface bone formation and reduces bone loss, but also decreases osteocyte apoptosis and mechanotransduction in ovariectomized rats: a pilot study","date":"2024-10-02","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.02.616263","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"16169070","id":"PMC_16169070","title":"A human protein-protein interaction network: a resource for annotating the proteome.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16169070","citation_count":1704,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14684825","id":"PMC_14684825","title":"Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays.","date":"2003","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/14684825","citation_count":1117,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8703060","id":"PMC_8703060","title":"Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency.","date":"1996","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8703060","citation_count":779,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8647860","id":"PMC_8647860","title":"Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8647860","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15304486","id":"PMC_15304486","title":"Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15304486","citation_count":351,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7818555","id":"PMC_7818555","title":"Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone.","date":"1995","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/7818555","citation_count":291,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9548757","id":"PMC_9548757","title":"Cross-class inhibition of the cysteine proteinases cathepsins K, L, and S by the serpin squamous cell carcinoma antigen 1: a kinetic analysis.","date":"1998","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9548757","citation_count":242,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7576232","id":"PMC_7576232","title":"Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution.","date":"1995","source":"Biological chemistry Hoppe-Seyler","url":"https://pubmed.ncbi.nlm.nih.gov/7576232","citation_count":224,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17207965","id":"PMC_17207965","title":"hORFeome v3.1: a resource of human open reading frames representing over 10,000 human genes.","date":"2007","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/17207965","citation_count":222,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14645229","id":"PMC_14645229","title":"Regulation of collagenase activities of human cathepsins by glycosaminoglycans.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14645229","citation_count":185,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19913121","id":"PMC_19913121","title":"Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.","date":"2009","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19913121","citation_count":164,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15161653","id":"PMC_15161653","title":"Pivotal role of cathepsin K in lung fibrosis.","date":"2004","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15161653","citation_count":163,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7805878","id":"PMC_7805878","title":"Molecular cloning of human cathepsin O, a novel endoproteinase and homologue of rabbit OC2.","date":"1995","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/7805878","citation_count":163,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9028530","id":"PMC_9028530","title":"Localization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistry.","date":"1997","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/9028530","citation_count":162,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11733367","id":"PMC_11733367","title":"Cathepsin k is a critical protease in synovial fibroblast-mediated collagen degradation.","date":"2001","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11733367","citation_count":148,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19396149","id":"PMC_19396149","title":"Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas.","date":"2009","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/19396149","citation_count":146,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12039963","id":"PMC_12039963","title":"Collagenase activity of cathepsin K depends on complex formation with chondroitin sulfate.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12039963","citation_count":144,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9033587","id":"PMC_9033587","title":"Crystal structure of human cathepsin K complexed with a potent inhibitor.","date":"1997","source":"Nature structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/9033587","citation_count":138,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17889653","id":"PMC_17889653","title":"An intracellular serpin regulates necrosis by inhibiting the induction and sequelae of lysosomal injury.","date":"2007","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/17889653","citation_count":133,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10719280","id":"PMC_10719280","title":"Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K.","date":"2000","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/10719280","citation_count":132,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12568399","id":"PMC_12568399","title":"Cathepsin K mRNA and protein expression in prostate cancer progression.","date":"2003","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/12568399","citation_count":131,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21983785","id":"PMC_21983785","title":"Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3.","date":"2011","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21983785","citation_count":123,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25422423","id":"PMC_25422423","title":"Structural basis of collagen fiber degradation by cathepsin K.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25422423","citation_count":121,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":38596,"output_tokens":5558,"usd":0.099579},"stage2":{"model":"claude-opus-4-6","input_tokens":9112,"output_tokens":3735,"usd":0.208402},"total_usd":0.673121,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":52266,"output_tokens":9173,"usd":0.147197},"round2_rules_fired":"R2","round2_stage2":{"model":"claude-opus-4-6","input_tokens":13019,"output_tokens":3208,"usd":0.217943}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"CTSK (cathepsin K) is a lysosomal cysteine protease with high sequence homology to cathepsins S and L (papain superfamily), abundantly and selectively expressed in osteoclasts, where it performs a specialized role in osteoclast-mediated bone resorption. The gene spans ~12.1 kb on chromosome 1q21, contains 8 exons and 7 introns, and lacks canonical TATA and CAAT boxes in its promoter.\",\n      \"method\": \"PCR genomic cloning, fluorescence in situ hybridization, ribonuclease protection assay, 5' RACE, promoter sequence analysis\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct genomic and expression characterization, replicated across studies\",\n      \"pmids\": [\"9143491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CTSK mutations causing pycnodysostosis (autosomal recessive osteosclerotic skeletal dysplasia) result in virtual absence of cathepsin K protein; even significantly reduced levels (50–80% of normal) are phenotypically silent, whereas complete absence causes disease, establishing that cathepsin K protein level directly determines osteoclast-mediated bone resorption capacity.\",\n      \"method\": \"DNA sequencing of CTSK gene, Western blot protein quantification in patient-derived cells, functional protein expression analysis\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct protein quantification with genotype–phenotype correlation, replicated in multiple pycnodysostosis studies\",\n      \"pmids\": [\"10491211\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Missense mutations in the mature domain of CTSK (e.g., L7P, Q165R, G194S, I249T, D250G, G319C) cause pycnodysostosis by disrupting protein folding as predicted by 3D structural modeling; the L7P mutation in the signal peptide specifically reduces expression level, implicating impaired targeting and translocation of the nascent lysosomal protein across the endoplasmic reticulum membrane.\",\n      \"method\": \"Sanger sequencing, Western blot of COS-7 cells transfected with mutant CTSK genes, 3D structural modeling\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional expression assay in transfected cells combined with structural modeling, multiple mutants tested\",\n      \"pmids\": [\"17397052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The CTSK Y283C mutation does not affect mRNA or protein levels of overexpressed CTSK in COS-7 cells but significantly reduces CTSK enzyme activity; Y283 is a conserved residue in papain-like cysteine proteases whose loss disrupts the hydrogen bond network and impairs autocatalytic self-cleavage of the enzyme, revealing the catalytic importance of this residue.\",\n      \"method\": \"COS-7 transfection, qRT-PCR, Western blot, CTSK enzyme activity assay, 3D structural modeling\",\n      \"journal\": \"Journal of dental research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — enzyme activity assay plus mutagenesis and structural modeling in a single study\",\n      \"pmids\": [\"25731711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Cathepsin K (CTK/CTSK) plays a direct causal role in the early-to-intermediate stages of osteoarthritis development; Ctsk-knockout mice show significantly delayed OA progression in a joint destabilization model, with reduced MMP-13 and ADAMTS-5 expression in chondrocytes and synovial cells, indicating CTSK acts upstream of these matrix-degrading enzymes.\",\n      \"method\": \"Ctsk-/- knockout mouse model, destabilization-induced OA surgery, modified Mankin histologic scoring, immunohistochemistry for CTK/MMP-13/ADAMTS-5/TRAP, histomorphometry\",\n      \"journal\": \"Arthritis and rheumatism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined phenotypic readout and pathway placement via downstream marker expression\",\n      \"pmids\": [\"21968827\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CTSK deficiency in Ctsk-/- mice delays OA progression by impairing osteoclast-mediated remodeling of subchondral bone and chondroclast-mediated remodeling of calcified cartilage; Ctsk-/- mice specifically show fewer physis-derived chondroclasts, with differential expression of Atp6v0d2, Tnfrsf11a, Ca2, Calcr, Ccr1, Gpr68, Itgb3, Nfatc1, and Syk in laser-captured osteoclasts and chondroclasts.\",\n      \"method\": \"Ctsk-/- knockout mouse model, DMM surgery, micro-CT, TRAP staining, laser-capture microdissection, targeted PCR arrays\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO with defined cellular phenotype, laser-capture transcriptomics, multiple orthogonal methods\",\n      \"pmids\": [\"29781506\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"RUNX2 promotes osteoclastogenesis and bone resorption through an AKT/NFATc1/CTSK axis: wild-type RUNX2 increases mTORC2 expression and activity, which phosphorylates AKT at Ser473, driving NFATc1 nuclear translocation and upregulating CTSK expression; mutant RUNX2 (c.514delT) abrogates this pathway.\",\n      \"method\": \"Stable RAW 264.7 cell lines expressing WT or mutant RUNX2, osteoclast differentiation assays, F-actin ring formation, bone resorption assay, Western blot for mTORC2/AKT phosphorylation/NFATc1, AKT inhibition and rescue experiments\",\n      \"journal\": \"Calcified tissue international\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pathway epistasis via inhibitor and rescue experiments with multiple orthogonal readouts\",\n      \"pmids\": [\"32008052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Cathepsin K (Ctsk) mediates TLR9-related autophagy in macrophages during periodontitis with rheumatoid arthritis; Ctsk inhibition suppresses TLR9 downstream signaling proteins and autophagy-related proteins (TFEB, LC3), and macrophage stimulation with CpG ODN (TLR9 agonist) confirmed that Ctsk specifically regulates cytokine production in response to TLR9 engagement.\",\n      \"method\": \"AAV-mediated Ctsk inhibition in DBA/J1 mouse model, siRNA knockdown in macrophages, CpG ODN stimulation, micro-CT, IHC, Western blot, qRT-PCR, immunofluorescence\",\n      \"journal\": \"Cell proliferation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo and in vitro confirmation, but mechanistic pathway placement relies on inhibitor studies\",\n      \"pmids\": [\"31737959\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Ctsk inhibition (BML-244) specifically reduces TLR9-dependent cytokine production in dendritic cells and T cells, decreasing IL-17-driven inflammatory responses and hard-tissue erosion in comorbid periodontitis-RA; Ctsk inhibition also decreased TLR4 and TLR9 expression in vivo.\",\n      \"method\": \"DBA/1 mouse model with BML-244 Ctsk inhibitor, in vitro macrophage stimulation, bone erosion quantification, flow cytometry for immune cell infiltration\",\n      \"journal\": \"Journal of clinical periodontology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — pharmacological inhibitor study with in vivo and in vitro confirmation, single lab\",\n      \"pmids\": [\"30636333\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CTSK promotes adipocyte differentiation; pharmacological inhibition of CTSK (CKSI) in high-fat diet obese mice reduces adipose tissue accumulation, HOMA index, and adipocyte size by downregulating PPARγ and C/EBPα transcription factors, establishing CTSK as a regulator of adipogenic differentiation.\",\n      \"method\": \"High-fat diet C57BL/6 mouse model with CTSK selective inhibitor, adipose tissue weight, HOMA index, adipocyte size measurement, qRT-PCR/Western blot for PPARγ and C/EBPα\",\n      \"journal\": \"Endocrine journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — pharmacological inhibitor in vivo with mechanistic marker analysis, single lab\",\n      \"pmids\": [\"25410008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CTSK functions as a potent collagenase in trabecular meshwork (TM) cells; siRNA-mediated CTSK knockdown disrupts collagen biogenesis and ECM homeostasis, increases intracellular calcium levels, and activates PRKD1-mediated actin polymerization through the LIMK1/SSH1/cofilin pathway, promoting focal adhesion maturation, suggesting CTSK regulates aqueous humor outflow and intraocular pressure.\",\n      \"method\": \"siRNA knockdown in human TM cells, unbiased proteomics, calcium level measurement, Western blot for LIMK1/SSH1/cofilin/caspase pathway, focal adhesion analysis\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — proteomics plus functional pathway analysis, but preprint only\",\n      \"pmids\": [\"bio_10.1101_2025.02.10.637394\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CTSK expression in CRPC is regulated by the IL-17 signaling pathway; CTSK promotes prostate cancer metastasis and proliferation by regulating EMT downstream markers, and CTSK expression correlates with M2 macrophage polarization creating a feedback circuit between TAMs and CRPC tissues.\",\n      \"method\": \"In vivo xenograft and in vitro experiments, DEG analysis, signal pathway enrichment, functional CTSK/IL-17 perturbation assays, TAM quantification by IHC\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo and in vitro functional experiments with pathway analysis, but single lab\",\n      \"pmids\": [\"36138018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In Ctsk+ osteoclasts, HIF-1α regulates lysosomal biogenesis through the TSC2-mTORC1-TFEB axis; conditional knockout of HIF-1α in Ctsk+ cells causes disorganized ruffled borders and defective lysosomal biogenesis, impairing calcified cartilage degradation and condylar morphogenesis.\",\n      \"method\": \"Conditional HIF-1α knockout in Ctsk-Cre mice (HIF-1α∆ctsk-cre), DTR transgenic ablation of Ctsk+ cells, histology, micro-CT, molecular pathway analysis of TSC2-mTORC1-TFEB\",\n      \"journal\": \"Journal of dental research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with defined molecular mechanism and phenotypic readout, multiple orthogonal methods\",\n      \"pmids\": [\"41108121\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"METTL3-mediated m6A methylation regulates Ctsk mRNA; loss of METTL3 in Ctsk+ lineage cells reduces Hedgehog signaling, impairing calvarial bone formation and suture development; restoration of Hh signaling rescues the abnormalities, placing CTSK-lineage cells downstream of METTL3/m6A/Hh axis.\",\n      \"method\": \"Ctsk-Cre conditional Mettl3 knockout mice, MeRIP sequencing, RNA sequencing, micro-CT, histology, genetic rescue via Sufu allele crossing and SAG21 administration\",\n      \"journal\": \"Journal of dental research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with MeRIP-seq and genetic rescue, multiple orthogonal methods\",\n      \"pmids\": [\"38752256\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"T-2 toxin induces cartilage ECM degradation by reducing METTL3-mediated m6A modification of Ctsk mRNA, thereby decreasing Ctsk expression; Ctsk silencing further aggravates ECM degradation, and increasing m6A levels by methionine supplementation mitigates cartilage damage, establishing a METTL3/m6A/Ctsk axis in chondrocyte ECM homeostasis.\",\n      \"method\": \"siRNA Ctsk knockdown in chondrocytes, MeRIP sequencing, RNA sequencing, dietary methionine supplementation in vivo, ECM marker quantification\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — MeRIP-seq plus functional KD and in vivo rescue, but single lab\",\n      \"pmids\": [\"39426235\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Ctsk+ periosteal stem cells (PSCs) in the orbital periosteum express CD200 and have osteogenic differentiation potential (CTSK co-localizes with osteocalcin in inner periosteal layer); these PSCs are mobilized after orbital fracture and have a transcriptomic profile distinct from bone marrow MSCs, particularly enriched for intramembranous osteogenesis pathways.\",\n      \"method\": \"Immunofluorescence, IHC, flow cytometry, transcriptome sequencing, multidirectional differentiation assay of isolated PSCs\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct characterization of CTSK+ cell population with functional differentiation assay and transcriptomics\",\n      \"pmids\": [\"37639249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Sfrp4 regulates Ctsk-lineage periosteal stem cell (PSC) function; Sfrp4 deletion decreases the pool of PSCs, impairs clonal multipotency (osteoblast and chondrocyte differentiation, bone organoid formation), and abolishes PTH-dependent increase in cortical thickness and periosteal bone formation, establishing Sfrp4 as a paracrine regulator of the Ctsk-lineage PSC niche.\",\n      \"method\": \"Sfrp4 global deletion mouse model, Ctsk-lineage tracing, flow cytometry for PSC quantification, bulk RNA sequencing, bone injury response assay, micro-CT, histomorphometry\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic deletion with RNA-seq and multiple functional assays in vivo and in vitro\",\n      \"pmids\": [\"37931101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The Sgk1-Stat3-Mycl signaling axis regulates osteoclastogenesis through direct transcriptional control of Ctsk; Sgk1 phosphorylates Stat3 at Tyr705, which upregulates Mycl, and Mycl directly binds the Ctsk promoter to drive expression; Mycl overexpression rescues osteoclast differentiation impaired by Sgk1 inhibition.\",\n      \"method\": \"Sgk1 inhibitor (GSK650394), Stat3 phosphorylation analysis, Mycl ChIP/promoter binding assay, Mycl overexpression rescue in osteoclasts, in vivo micro-CT of trabecular bone\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct promoter binding demonstrated, rescue experiment confirms pathway position, in vivo validation\",\n      \"pmids\": [\"41266497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Liquiritin promotes lysosomal degradation of CXCL1 in tumor-associated macrophages by upregulating CTSK expression; CTSK-mediated lysosomal proteolysis of CXCL1 suppresses TAM-driven breast cancer neoangiogenesis, establishing a role for CTSK in lysosomal degradation of secreted chemokines in macrophages.\",\n      \"method\": \"TAM-membrane-capture/LC-MS, TAM/CXCL1 ELISA, CXCL1 and lysosome co-localization assay, CTSK expression analysis, CXCL1 overexpression rescue, zebrafish xenotransplantation, mouse xenograft model\",\n      \"journal\": \"Phytomedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-localization and rescue experiments in vitro and in vivo, but single lab, novel finding\",\n      \"pmids\": [\"41072283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"Tucatinib directly binds to and inhibits CTSK enzymatic activity (confirmed by microscale thermophoresis, molecular docking, and CTSK activity assays) and simultaneously inhibits NFATc1-driven osteoclast differentiation by maintaining mitochondrial homeostasis through inhibition of DRP1 phosphorylation at Ser616 and reducing mitochondrial ROS, revealing a DRP1/NFATc1/CTSK signaling axis in osteoclastogenesis.\",\n      \"method\": \"Microscale thermophoresis (MST), molecular docking, CTSK enzymatic activity assay, DRP1 phosphorylation assay, mtROS measurement, NFATc1 nuclear translocation assay, ovariectomized mouse model, micro-CT\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct binding assay (MST), enzymatic activity assay, and mechanistic pathway analysis in vitro plus in vivo validation\",\n      \"pmids\": [\"41974330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ARNT transcripts can read through the ARNT-CTSK intergenic region and extend into CTSK as far as intron 3; this transcriptional read-through may negatively impact CTSK transcript levels by interfering with CTSK expression. Additionally, novel CTSK transcripts with alternate 5' splicing initiated from a cryptic upstream promoter were identified.\",\n      \"method\": \"RT-PCR spanning ARNT-CTSK intergenic region, quantitative RT-PCR from multiple tissues, EST sequence analysis\",\n      \"journal\": \"Comparative and functional genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — RT-PCR and qRT-PCR characterization, single lab, no functional perturbation experiment\",\n      \"pmids\": [\"18629217\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CTSK (cathepsin K) is a lysosomal cysteine protease of the papain superfamily, selectively and abundantly expressed in osteoclasts, where it degrades type I collagen and other bone matrix proteins to mediate bone resorption; its transcription is directly regulated by NFATc1 downstream of RANK signaling (via the Sgk1-Stat3-Mycl-Ctsk axis), and by RUNX2 through an mTORC2/AKT/NFATc1 cascade; in osteoclasts, HIF-1α controls lysosomal biogenesis through a TSC2-mTORC1-TFEB axis in a CTSK-dependent manner; CTSK also regulates ECM homeostasis and actin cytoskeletal dynamics in non-osteoclast cells (trabecular meshwork, adipocytes, macrophages), promotes lysosomal degradation of secreted chemokines (CXCL1) in macrophages, and marks a population of periosteal and calvarial stem cells that contribute to bone repair and homeostasis.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper first, then extract discoveries only from KEPT papers.\n\n**Classification summary:**\n- Papers 1, 3, 4, 6, 9, 14, 15, 22 (corpus), 33, 34 = EXCLUDE (PknD/Mycobacterium/Chlamydia/Anabaena — symbol collision, not CTSK)\n- Papers 19, 28 (corpus), 37, 47 = EXCLUDE (CTSO, not CTSK)\n- Papers 57 = EXCLUDE (fish CTSK/IHNV — incompatible context, likely symbol collision in salmon)\n- Papers 74 = EXCLUDE (zyxin study, CTSK only mentioned as differentially expressed gene, no mechanistic finding about CTSK)\n- All remaining papers about human/mouse CTSK = KEEP\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"Pycnodysostosis (autosomal recessive osteosclerosis) is caused by loss-of-function mutations in cathepsin K (CTSK), establishing that CTSK is a lysosomal cysteine protease essential for osteoclast-mediated bone resorption; nonsense, missense, and stop-codon mutations were identified in affected patients.\",\n      \"method\": \"Genetic linkage mapping, Sanger sequencing of patient DNA, transient expression of mutant cDNA with Western blot to confirm absence of protein\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — foundational disease-gene identification, multiple mutation types, protein expression validation; independently replicated across many subsequent studies\",\n      \"pmids\": [\"8703060\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Human cathepsin K was molecularly cloned and identified as a novel cysteine proteinase of the papain superfamily, predominantly expressed in osteoclasts and osteoclastomas, implicating it as the major protease in osteoclastic bone resorption.\",\n      \"method\": \"cDNA library screening using rabbit OC-2 probe, Northern blot analysis of tissue distribution\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — original cloning with expression characterization; independently confirmed by multiple labs\",\n      \"pmids\": [\"7818555\", \"7576232\", \"7805878\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Recombinant cathepsin K is a cysteine protease that degrades type I collagen and osteonectin (bone matrix proteins) in vitro; it is activated upon removal of its inhibitory pro-sequence, is inhibited by E-64 and leupeptin but not by pepstatin or EDTA, and cleaves fluorogenic peptide substrates.\",\n      \"method\": \"Baculovirus expression, purification, in vitro enzyme activity assays with fluorogenic peptides, collagen degradation assay, inhibitor profiling\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro with multiple substrates and inhibitor characterization\",\n      \"pmids\": [\"8647860\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Crystal structure of human cathepsin K complexed with a potent inhibitor was determined, revealing the active-site architecture of this papain-family cysteine protease.\",\n      \"method\": \"X-ray crystallography\",\n      \"journal\": \"Nature structural biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with functional inhibitor complex\",\n      \"pmids\": [\"9033587\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CTSK gene was mapped to chromosome 1q21 by fluorescence in situ hybridization; genomic organization established as 8 exons/7 introns spanning ~12.1 kb; a single transcription start site 49 bp upstream of the initiator Met was identified; the 5' flanking region lacks canonical TATA/CAAT boxes, suggesting non-canonical transcriptional regulation.\",\n      \"method\": \"FISH, PCR on genomic DNA, P1 clone isolation, ribonuclease protection assay, 5' RACE\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct experimental mapping and promoter characterization\",\n      \"pmids\": [\"9143491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Cathepsin K protein is specifically localized to osteoclasts within bone tissue; in actively resorbing osteoclasts, immunostaining localizes cathepsin K at the ruffled border, and in giant cell tumors it is found in lysosomal vacuoles that fuse with the cell membrane.\",\n      \"method\": \"In situ hybridization and immunohistochemistry on bone and giant cell tumor sections\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct localization with functional spatial context (ruffled border during active resorption); replicated across multiple studies\",\n      \"pmids\": [\"9028530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"SCCA1 (squamous cell carcinoma antigen 1), a serpin, is a potent cross-class inhibitor of cathepsin K, acting with 1:1 stoichiometry and second-order rate constants ≥1×10⁵ M⁻¹s⁻¹, forming stable complexes via a mechanism similar to serpin-serine protease interactions involving cleavage at the reactive site loop.\",\n      \"method\": \"Kinetic analysis (second-order rate constants, stoichiometry, complex stability), SDS-PAGE to detect stable inhibitor-protease complex\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — rigorous kinetic analysis with mechanistic characterization of inhibitor-enzyme interaction\",\n      \"pmids\": [\"9548757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Complete mouse Ctsk gene was characterized (8 exons, 7 introns, ~10.1 kb), showing conserved exon sizes with the human gene; Ctsk is located ~4.5 kb downstream of the Arnt gene on mouse chromosome 3.\",\n      \"method\": \"Genomic cloning, sequence analysis, chromosomal mapping\",\n      \"journal\": \"Matrix biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct genomic characterization; single study\",\n      \"pmids\": [\"10372556\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CTSK mutations that reduce cathepsin K protein to virtually absent levels cause pycnodysostosis, while ~50-80% reduced protein levels (in heterozygous parents) have no phenotypic effect, establishing a threshold for cathepsin K in bone resorption.\",\n      \"method\": \"DNA sequencing of patient/family members, Western blot for protein expression levels\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — protein quantification in affected individuals and carrier parents with clear genotype-phenotype dose-response\",\n      \"pmids\": [\"10491211\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Recombinant human cathepsin K cleaves the trivalently cross-linked ICTP (carboxyterminal telopeptide of type I collagen) at two sites between the phenylalanine-rich region and the cross-link, destroying ICTP immunoreactivity; MMP-9, MMP-1, and MMP-13 do not have this effect, distinguishing cathepsin K-mediated from MMP-mediated collagen degradation in bone.\",\n      \"method\": \"In vitro proteolytic cleavage assay with recombinant cathepsin K and MMPs, immunochemical detection of ICTP degradation products\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with multiple proteases compared; identifies specific cleavage sites\",\n      \"pmids\": [\"10719280\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Cathepsin K is expressed in synovial fibroblasts (SFs) in rheumatoid arthritis and is the critical protease for SF-mediated intralysosomal collagen degradation; co-culture of SFs on cartilage showed collagen fibril phagocytosis and lysosomal hydrolysis blocked by cathepsin K inhibitor but not by inhibitors of cathepsins L, B, and S. Cathepsin K also has potent aggrecan-degrading activity, and cathepsin K-generated aggrecan fragments potentiate its own collagenolytic activity.\",\n      \"method\": \"Immunostaining of RA joint specimens, primary SF cell culture, co-culture on cartilage disks, selective protease inhibitors, collagen degradation assay\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including selective inhibition in cell culture and cartilage co-culture; identifies novel substrate (aggrecan) and positive feedback mechanism\",\n      \"pmids\": [\"11733367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Cathepsin K collagenase activity requires complex formation with chondroitin sulfate glycosaminoglycans; the active complex is an oligomer of five cathepsin K and five chondroitin sulfate molecules. Monomeric cathepsin K has no collagenase activity but retains gelatinase activity. The Y212C pycnodysostosis-causing mutant cannot form these complexes and therefore lacks collagenase activity despite retaining gelatinase activity.\",\n      \"method\": \"In vitro complex formation assay, collagen and gelatin degradation assays, analysis of pycnodysostosis mutant Y212C\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro with mutant validation linking complex formation to disease; mechanistically definitive\",\n      \"pmids\": [\"12039963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Chondroitin sulfate and keratan sulfate (GAGs predominant in bone and cartilage) enhance cathepsin K's collagenolytic activity, while dermatan sulfate, heparan sulfate, and heparin selectively inhibit it. Complex formation with GAGs is unique to cathepsin K among papain-like cysteine proteases; cathepsins L and S do not form these complexes and their collagenase activity is inhibited by GAGs at 37°C.\",\n      \"method\": \"In vitro collagen degradation assays with different GAGs, comparative analysis across cathepsin family members\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — rigorous in vitro reconstitution with structure-activity analysis across multiple GAGs and cathepsins\",\n      \"pmids\": [\"14645229\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"p38 MAP kinase is required for maximal RANKL-induced cathepsin K gene expression during osteoclastogenesis; RANKL-induced NFATc1 is phosphorylated by activated p38 MAP kinase, then forms a complex with PU.1 in osteoclast nuclei; NFATc1, PU.1, and MITF synergistically enhance cathepsin K promoter activity.\",\n      \"method\": \"Reporter gene assay with cathepsin K 5'-deletion constructs, overexpression in RAW264 cells, p38-specific inhibitor (SB203580), nuclear localization studies\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — promoter dissection, transcription factor overexpression, chemical inhibition, nuclear complex formation; multiple orthogonal methods\",\n      \"pmids\": [\"15304486\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Cathepsin K plays a pivotal role in lung matrix homeostasis; CTSK-/- mice develop significantly more extracellular matrix deposition and fibrosis after bleomycin challenge. Primary lung fibroblasts from CTSK-/- mice show decreased collagenolytic activity, and human pulmonary fibroblasts upregulate cathepsin K activity during activation.\",\n      \"method\": \"Bleomycin-induced fibrosis model in Ctsk knockout mice, primary fibroblast collagenolytic activity assays, gene expression analysis\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse model with defined phenotype plus in vitro fibroblast activity assays; multiple orthogonal methods\",\n      \"pmids\": [\"15161653\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ARNT transcripts read through the ARNT-CTSK intergenic region and extend into CTSK intron 3 (~3.7 kb downstream of the longest known ARNT mRNA); this may negatively impact CTSK transcript levels by interfering with CTSK expression. Novel CTSK transcripts with alternate 5' splicing and a cryptic upstream promoter were also identified.\",\n      \"method\": \"RT-PCR spanning ARNT-CTSK intergenic region, quantitative RT-PCR from multiple tissues, EST sequence analysis\",\n      \"journal\": \"Comparative and functional genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — direct RT-PCR evidence for read-through transcription; functional consequence (interference with CTSK expression) is inferred rather than experimentally proven\",\n      \"pmids\": [\"18629217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Nine novel CTSK mutations causing pycnodysostosis were characterized; the L7P mutation in the signal peptide significantly reduces protein expression, indicating the signal peptide is required for targeting and translocation of cathepsin K across the ER membrane. Other missense mutations were predicted by 3D structural modeling to cause incorrect protein folding.\",\n      \"method\": \"Sanger sequencing, Western blot of COS-7 cells transfected with mutant CTSK cDNAs, 3D structural modeling\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct expression assay in transfected cells linking specific mutation to loss of ER translocation\",\n      \"pmids\": [\"17397052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Cathepsin K is expressed by translocation renal cell carcinomas bearing TFE3 or TFEB translocations; overexpression of TFEB (or related TFE family members including MITF) drives cathepsin K expression, identifying CTSK as a transcriptional target of the MiTF/TFE transcription factor family.\",\n      \"method\": \"Immunohistochemistry of cytogenetically confirmed translocation RCCs and control renal neoplasms (n=210+ cases)\",\n      \"journal\": \"Modern pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — IHC-based localization linking TFE family overexpression to cathepsin K expression; no direct transcriptional assay\",\n      \"pmids\": [\"19396149\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Ctsk knockout mice show delayed osteoarthritic progression in a joint destabilization model; CTK-positive chondrocytes and synovial cells are identified as sources of cathepsin K driving OA, and loss of cathepsin K reduces expression of MMP-13 and ADAMTS-5 in chondrocytes.\",\n      \"method\": \"Ctsk-/- mouse model, destabilization of medial meniscus surgery, histologic scoring (modified Mankin), immunohistochemistry for CTK, MMP-13, ADAMTS-5, TRAP\",\n      \"journal\": \"Arthritis and rheumatism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with defined OA phenotype and molecular pathway readout (downstream protease expression)\",\n      \"pmids\": [\"21968827\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Structural basis for cathepsin K collagen fiber degradation was established: cathepsin K forms elongated C-shaped protein dimers that constitute the collagenolytically active unit; glycosaminoglycans bridge the dimer and provide a putative collagen-binding interface. Residues Q21 and Q92 (outside the active site) participate in collagen unfolding; mutations at these sites or perturbation of the dimer interface abolish fiber degradation without affecting gelatin or peptide hydrolysis. Cathepsin K binds specifically at the fibrillar gap region of collagen fibers.\",\n      \"method\": \"Crystal structure of cathepsin K dimer, molecular modeling of collagen binding, site-directed mutagenesis of Q21/Q92 and dimer interface, scanning electron microscopy of fiber binding, Edman degradation to identify cleavage sites\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure combined with mutagenesis, SEM, and Edman degradation in a single study; mechanistically definitive\",\n      \"pmids\": [\"25422423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Novel compound heterozygous CTSK mutations (p.W29X and p.Y283C) cause pycnodysostosis with dental abnormalities including thickened, softened cementum; the Y283C mutation does not affect mRNA or protein levels but significantly reduces CTSK enzyme activity, and structural modeling shows Y283C disrupts the hydrogen network affecting enzyme self-cleavage/activation.\",\n      \"method\": \"Histology, atomic force microscopy, micro-CT, in vitro enzyme activity assay in COS-7 cells overexpressing mutant CTSK, 3D structural modeling\",\n      \"journal\": \"Journal of dental research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct enzyme activity measurement of mutant vs wild-type in expression system; single study\",\n      \"pmids\": [\"25731711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Ctsk-/- mice show delayed OA progression with reduced chondroclast numbers in the growth plate relative to WT; differential gene expression in laser-captured osteoclasts and chondroclasts from Ctsk-/- mice revealed altered expression of Atp6v0d2, Tnfrsf11a, Ca2, Calcr, Ccr1, Gpr68, Itgb3, Nfatc1, and Syk, suggesting cathepsin K differentially regulates chondroclastogenesis.\",\n      \"method\": \"Ctsk-/- mouse model, DMM surgery, laser capture microdissection, targeted PCR arrays, histomorphometry\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse with laser-captured cell-specific gene expression; single study\",\n      \"pmids\": [\"29781506\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Cathepsin K (Ctsk) regulates TLR9 signaling and autophagy in the context of periodontitis with rheumatoid arthritis; inhibition of Ctsk in vivo (via AAV or BML-244) reduces TLR9, TFEB, LC3, macrophage infiltration, and inflammatory cytokines in periodontal lesions; in vitro, Ctsk inhibition specifically suppresses TLR9-downstream signaling proteins and autophagy-related proteins in macrophages.\",\n      \"method\": \"DBA/J1 mouse model, AAV-mediated Ctsk knockdown, BML-244 inhibitor, Western blot, IHC, qRT-PCR, IF, siRNA in macrophages, CpG ODN stimulation\",\n      \"journal\": \"Cell proliferation / Journal of clinical periodontology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic/pharmacological inhibition with mechanistic pathway analysis in vitro; two independent publications\",\n      \"pmids\": [\"31737959\", \"30636333\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"RUNX2 promotes osteoclast differentiation and bone resorption through the AKT/NFATc1/CTSK axis: wild-type RUNX2 increases mTORC2 activity and specifically promotes AKT phosphorylation at Ser473, which enhances NFATc1 nuclear translocation and increases CTSK expression; AKT inhibition abolishes this, and constitutively active AKT rescues osteoclastogenesis in mutant cells.\",\n      \"method\": \"Stable RAW264.7 cell lines expressing WT or mutant RUNX2, F-actin ring formation assay, bone resorption pit assay, mTORC2/AKT inhibition, NFATc1 nuclear translocation assay, Western blot\",\n      \"journal\": \"Calcified tissue international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway epistasis with genetic rescue experiment; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"32008052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CTSK mediates castration-resistant prostate cancer (CRPC) growth and metastasis via the IL-17 signaling/CTSK/EMT axis; CTSK promotes EMT to drive metastasis and proliferation, and CTSK expression is linked to M2 macrophage polarization, forming a feedback circuit between M2 TAMs and CRPC tissue.\",\n      \"method\": \"In vivo and in vitro experiments in CRPC cells, gene knockdown/overexpression, IL-17 pathway manipulation, M2 macrophage co-culture, EMT marker analysis\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple in vitro/in vivo assays; single lab\",\n      \"pmids\": [\"36138018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Loss of Trp53 and Rb1 in Ctsk-expressing cells drives osteosarcoma via YAP activation; YAP/TEAD1 complex binds the Glut1 promoter to upregulate glucose transporter expression, leading to overactive glucose metabolism; ablation of YAP signaling inhibits energy metabolism and delays osteosarcoma progression in Ctsk-Cre;Trp53f/f/Rb1f/f mice.\",\n      \"method\": \"Conditional KO mouse model (Ctsk-Cre;Trp53f/f/Rb1f/f), mechanistic studies of YAP expression/activity, promoter luciferase for Glut1, YAP inhibition\",\n      \"journal\": \"MedComm\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic model with mechanistic promoter assay; single lab\",\n      \"pmids\": [\"35615117\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Sfrp4 is required for maintenance of Ctsk-lineage periosteal stem cells (PSCs); Sfrp4 deletion reduces the PSC pool, impairs clonal multipotency for osteoblast/chondrocyte differentiation, and abolishes the PTH-dependent increase in PSC numbers and cortical bone formation; Sfrp4 regulates Ctsk-lineage PSCs by maintaining Wnt signaling and Hh pathway-associated genes.\",\n      \"method\": \"Sfrp4 global deletion mouse model, Ctsk-lineage tracing, clonal multipotency assays, bulk RNA sequencing of Ctsk-lineage PSCs, PTH treatment, periosteal injury model\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic deletion with lineage tracing, RNA-seq, and functional rescue; single study\",\n      \"pmids\": [\"37931101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"METTL3-mediated m6A modification regulates Ctsk expression in calvarial Ctsk+ stem cells; loss of Mettl3 in Ctsk+ lineage cells reduces Hedgehog (Hh) signaling, delays suture formation, and impairs calvarial bone formation; restoration of Hh signaling partially rescues these defects.\",\n      \"method\": \"Conditional Mettl3 KO in Ctsk-Cre mice, MeRIP-seq plus RNA-seq, micro-CT, histology, Sufu allele crossing for Hh restoration, SAG21 local administration\",\n      \"journal\": \"Journal of dental research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with m6A sequencing and genetic rescue; single study\",\n      \"pmids\": [\"38752256\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"T-2 toxin induces cartilage ECM degradation by downregulating METTL3-mediated m6A methylation of Ctsk mRNA; METTL3 silencing exacerbates HT-2 toxin-induced ECM degradation, while Ctsk silencing also aggravates it, suggesting Ctsk normally has a protective role in cartilage maintenance; dietary methionine supplementation increases m6A levels in vivo and mitigates cartilage damage.\",\n      \"method\": \"MeRIP-seq, RNA-seq, siRNA knockdown of METTL3 and Ctsk in chondrocytes, in vivo methionine supplementation\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — m6A sequencing combined with knockdown and in vivo rescue; single study\",\n      \"pmids\": [\"39426235\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Loss of CTSK in trabecular meshwork (TM) cells disrupts collagen biogenesis and ECM homeostasis; siRNA knockdown of CTSK increases intracellular calcium, activates PRKD1 which drives LIMK1/SSH1/cofilin-mediated actin polymerization and focal adhesion maturation, and downregulates RhoQ and myosin motor proteins, indicating altered mechanotransduction; apoptotic markers increase without caspase 3/7 activation, suggesting apoptosis-independent remodeling.\",\n      \"method\": \"siRNA-mediated CTSK knockdown in human TM cells, unbiased proteomics (mass spectrometry), intracellular calcium measurement, actin/focal adhesion imaging\",\n      \"journal\": \"bioRxiv (preprint)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — unbiased proteomics plus functional assays; preprint, single study\",\n      \"pmids\": [\"bio_10.1101_2025.02.10.637394\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"HIF-1α in Ctsk+ osteoclasts regulates lysosomal biogenesis via the TSC2-mTORC1-TFEB axis; conditional HIF-1α knockout in Ctsk+ cells causes disorganized ruffled borders, defective lysosomal biogenesis, and abnormal condylar morphogenesis with calcified cartilage accumulation and impaired subchondral bone formation.\",\n      \"method\": \"DTR transgenic and conditional HIF-1α knockout (HIF-1α∆ctsk-cre) mouse models, histology, micro-CT, cellular ultrastructure analysis, gene expression\",\n      \"journal\": \"Journal of dental research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with defined cellular phenotype and pathway identification; single study\",\n      \"pmids\": [\"41108121\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Sgk1 regulates osteoclastogenesis via Stat3 phosphorylation at Tyr705, leading to Mycl upregulation; Mycl directly binds the Ctsk promoter and drives Ctsk transcription; Mycl overexpression rescues osteoclast differentiation impaired by Sgk1 inhibition, defining a Sgk1-Stat3-Mycl-Ctsk signaling axis.\",\n      \"method\": \"Sgk1 inhibitor (GSK650394), Mycl overexpression rescue in osteoclasts, Ctsk promoter binding assay, in vivo micro-CT in Sgk1 inhibitor-treated mice\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic rescue experiment with promoter binding evidence and in vivo validation; single study\",\n      \"pmids\": [\"41266497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Tucatinib directly binds and inhibits CTSK enzymatic activity (confirmed by microscale thermophoresis and CTSK activity assays); it also suppresses NFATc1-driven osteoclast differentiation by inhibiting DRP1 phosphorylation at Ser616, reducing mitochondrial ROS and stabilizing mitochondrial dynamics, thereby defining a DRP1/NFATc1/CTSK axis in osteoclastogenesis.\",\n      \"method\": \"Virtual screening, microscale thermophoresis, CTSK activity assays, DRP1 phosphorylation assay, mtROS measurement, ovariectomized mouse model\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — direct binding confirmed by biophysical assay plus enzyme activity and in vivo validation; single study\",\n      \"pmids\": [\"41974330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Liquiritin enhances CTSK-mediated lysosomal degradation of CXCL1 in tumor-associated macrophages (TAMs); liquiritin accumulates in TAM lysosomes, increases CXCL1 and lysosome colocalization, and upregulates CTSK expression to accelerate CXCL1 degradation, thereby suppressing CXCL1-driven breast cancer neoangiogenesis.\",\n      \"method\": \"TAM membrane-capture/LC-MS screening, CXCL1 ELISA, lysosome/CXCL1 colocalization assay, CTSK expression measurement, in vivo breast cancer xenograft and zebrafish models\",\n      \"journal\": \"Phytomedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic colocalization and functional rescue with in vivo validation; single lab\",\n      \"pmids\": [\"41072283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Caffeine directly enhances osteoclast differentiation and maturation by activating p38 MAP kinase, which induces Mitf expression and transcriptional upregulation of DC-STAMP (cell fusion), and ultimately increases cathepsin K (CtsK) and TRAP expression; the p38 inhibitor SB203580 blocks caffeine-induced CtsK upregulation.\",\n      \"method\": \"TRAP staining of osteoclasts, p38 inhibitor, real-time PCR, luciferase reporter for DC-STAMP\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — pharmacological pathway dissection with reporter assay; places CTSK downstream of p38/Mitf in osteoclast maturation\",\n      \"pmids\": [\"23434822\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Cathepsin K is expressed by prostate cancer cells and is enzymatically active (collagenase and fluorogenic peptide activity); cathepsin K mRNA and protein are present in prostate cancer cell lines and primary tumors, with significantly higher expression in bone metastases than primary cancer, and serum NTx (a cathepsin K-mediated bone resorption marker) is elevated in patients with bone metastases.\",\n      \"method\": \"RT-PCR, in situ hybridization, immunohistochemistry, Western blot after immunoprecipitation, fluorogenic enzyme activity assay, type I collagen degradation assay\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct enzymatic activity confirmed in cancer cell lines; single study\",\n      \"pmids\": [\"12568399\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Cathepsin K (CTSK) is a lysosomal cysteine protease of the papain superfamily, highly expressed in osteoclasts (localizing to the ruffled border during active resorption), that degrades type I collagen, osteopontin, aggrecan, and other ECM proteins; its unique and potent collagenase activity requires oligomeric complex formation with chondroitin sulfate glycosaminoglycans (5:5 stoichiometry) facilitated by a dimer interface involving residues Q21/Q92, while monomeric enzyme retains only gelatinase activity; CTSK transcription during osteoclastogenesis is cooperatively regulated by RANKL-induced p38 MAP kinase phosphorylation of NFATc1, which complexes with PU.1 and MITF at the CTSK promoter, and is also driven by an Sgk1-Stat3-Mycl axis; CTSK is inhibited by SCCA1 serpin via stable 1:1 complex formation; loss-of-function mutations in CTSK cause pycnodysostosis by eliminating collagenolytic activity in osteoclasts; beyond bone, CTSK is active in synovial fibroblasts driving RA cartilage destruction, in lung fibroblasts maintaining ECM homeostasis, in CTSK+ periosteal stem cells regulated by Sfrp4/Wnt and METTL3/Hedgehog signaling, and in tumor-associated macrophages where it mediates lysosomal degradation of CXCL1 to modulate angiogenesis.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CTSK (cathepsin K) is a lysosomal cysteine protease of the papain superfamily that serves as the principal collagenase in osteoclast-mediated bone resorption and a broader regulator of extracellular matrix homeostasis, immune signaling, and stem cell identity across multiple tissues. Abundantly expressed in osteoclasts, CTSK degrades type I collagen and bone matrix proteins; its transcription is controlled by NFATc1 downstream of RANK signaling via a Sgk1–Stat3–Mycl axis (Mycl directly binds the Ctsk promoter), and by RUNX2 through an mTORC2/AKT/NFATc1 cascade [PMID:41266497, PMID:32008052]. Loss-of-function mutations cause pycnodysostosis, an autosomal recessive osteosclerotic dysplasia, with disease severity correlating with complete absence of cathepsin K protein rather than partial reduction [PMID:10491211, PMID:17397052]. Beyond bone, CTSK marks periosteal stem cells with osteogenic and chondrogenic potential, promotes lysosomal degradation of the chemokine CXCL1 in macrophages, regulates adipogenesis through PPARγ/C/EBPα, and contributes to cartilage ECM homeostasis and osteoarthritis progression [PMID:37931101, PMID:41072283, PMID:25410008, PMID:21968827].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Identifying the genomic organization and osteoclast-selective expression of CTSK established that a specialized cysteine protease of the papain family is dedicated to bone resorption.\",\n      \"evidence\": \"PCR genomic cloning, FISH, ribonuclease protection assay in human tissues\",\n      \"pmids\": [\"9143491\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Promoter regulatory elements driving osteoclast selectivity were not characterized\", \"Enzymatic substrates in vivo were not identified\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Genotype–phenotype correlation in pycnodysostosis patients demonstrated that complete loss of cathepsin K protein—not partial reduction—causes disease, establishing a threshold model for CTSK dosage in bone resorption.\",\n      \"evidence\": \"CTSK mutation sequencing and Western blot protein quantification in patient-derived cells\",\n      \"pmids\": [\"10491211\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which heterozygous carriers maintain sufficient protein levels was not explored\", \"Whether residual enzymatic activity from misfolded protein contributes was unknown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Structural modeling and expression assays of multiple pycnodysostosis-causing missense mutations revealed that disease arises from disrupted protein folding (mature domain mutations) or impaired ER translocation (signal peptide L7P), linking 3D structure to pathogenesis.\",\n      \"evidence\": \"Sanger sequencing, Western blot of COS-7 transfected with mutant CTSK, 3D structural modeling\",\n      \"pmids\": [\"17397052\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No in vitro enzymatic activity measurements for individual mutants\", \"Crystal structure of mutant proteins not determined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Ctsk knockout mice showed delayed osteoarthritis progression with reduced MMP-13 and ADAMTS-5 expression, placing CTSK upstream of other matrix-degrading enzymes and revealing its causal role beyond physiological bone remodeling.\",\n      \"evidence\": \"Ctsk−/− mice with surgically induced OA, histologic scoring, immunohistochemistry\",\n      \"pmids\": [\"21968827\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct proteolytic substrates in cartilage were not identified\", \"Whether CTSK acts cell-autonomously in chondrocytes versus osteoclasts was unresolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Pharmacological CTSK inhibition reduced adipose tissue accumulation and adipocyte size by downregulating PPARγ and C/EBPα, establishing a non-skeletal role for CTSK in adipogenic differentiation.\",\n      \"evidence\": \"Selective CTSK inhibitor in high-fat diet C57BL/6 mice with qRT-PCR/Western blot for adipogenic markers\",\n      \"pmids\": [\"25410008\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether CTSK acts intracellularly or extracellularly in adipocytes is unknown\", \"Off-target inhibitor effects not excluded\", \"Genetic confirmation in adipocyte-specific KO lacking\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"The Y283C mutation preserved protein expression but abolished enzymatic activity by disrupting the hydrogen bond network required for autocatalytic self-cleavage, pinpointing a catalytically essential residue in the papain fold.\",\n      \"evidence\": \"COS-7 transfection, CTSK enzyme activity assay, 3D structural modeling\",\n      \"pmids\": [\"25731711\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Recombinant purified enzyme kinetics not reported\", \"Structural confirmation by crystallography absent\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Refined analysis of Ctsk−/− OA joints showed that CTSK deficiency impairs both osteoclast-mediated subchondral bone remodeling and chondroclast-mediated calcified cartilage remodeling, with differential gene expression (Nfatc1, Atp6v0d2, Itgb3) distinguishing the two cell types.\",\n      \"evidence\": \"Ctsk−/− mice, DMM surgery, micro-CT, laser-capture microdissection with targeted PCR arrays\",\n      \"pmids\": [\"29781506\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether chondroclasts represent a distinct lineage from osteoclasts remains unclear\", \"Functional rescue not performed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"CTSK was linked to innate immune signaling: its inhibition suppressed TLR9-dependent cytokine production and autophagy markers (TFEB, LC3) in macrophages and dendritic cells, revealing a role in inflammatory bone erosion during periodontitis–RA comorbidity.\",\n      \"evidence\": \"Ctsk inhibitor (BML-244) and siRNA KD in macrophages, CpG ODN TLR9 stimulation, DBA/1 mouse models\",\n      \"pmids\": [\"31737959\", \"30636333\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular interaction between CTSK and TLR9 pathway components not demonstrated\", \"Reliance on pharmacological inhibitor limits specificity claims\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"RUNX2 was shown to drive CTSK expression through an mTORC2→AKT(Ser473)→NFATc1 axis during osteoclastogenesis, with AKT inhibition blocking the pathway and rescue experiments confirming epistatic ordering.\",\n      \"evidence\": \"RAW 264.7 cells expressing WT/mutant RUNX2, bone resorption assay, Western blot for mTORC2/AKT/NFATc1, AKT inhibition and rescue\",\n      \"pmids\": [\"32008052\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether RUNX2 directly binds the CTSK promoter or acts only via NFATc1 is unresolved\", \"Contribution of mTORC1 versus mTORC2 not fully separated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Ctsk was established as a lineage marker for periosteal stem cells (PSCs) with osteogenic and chondrogenic potential; Sfrp4 deletion depleted the Ctsk+ PSC pool and abolished PTH-stimulated periosteal bone formation, defining a paracrine regulatory niche.\",\n      \"evidence\": \"Ctsk-lineage tracing, Sfrp4−/− mice, flow cytometry, RNA-seq, bone injury response, micro-CT\",\n      \"pmids\": [\"37639249\", \"37931101\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CTSK enzymatic activity is functionally required in PSCs or merely marks them is unknown\", \"Human PSC equivalence not confirmed\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"METTL3-mediated m6A methylation was shown to regulate Ctsk mRNA post-transcriptionally; in Ctsk-lineage cells, METTL3 loss impaired Hedgehog signaling and calvarial bone formation, while in chondrocytes, reduced m6A on Ctsk mRNA contributed to ECM degradation, establishing epitranscriptomic control of CTSK expression.\",\n      \"evidence\": \"Ctsk-Cre conditional Mettl3 KO, MeRIP-seq, genetic rescue via Sufu crossing and SAG21; siRNA Ctsk KD in chondrocytes with methionine supplementation\",\n      \"pmids\": [\"38752256\", \"39426235\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific m6A sites on Ctsk mRNA and their reader proteins are not mapped\", \"Whether m6A affects Ctsk mRNA stability or translation is unresolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"The Sgk1–Stat3–Mycl transcriptional axis was identified as a direct regulator of Ctsk: Sgk1 phosphorylates Stat3 at Tyr705, upregulating Mycl, which binds the Ctsk promoter; Mycl overexpression rescued Sgk1-inhibited osteoclastogenesis, completing a signaling cascade from kinase to CTSK transcription.\",\n      \"evidence\": \"Sgk1 inhibitor, Stat3 phosphorylation analysis, Mycl ChIP on Ctsk promoter, Mycl overexpression rescue, micro-CT in vivo\",\n      \"pmids\": [\"41266497\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Mycl cooperates with NFATc1 at the Ctsk promoter is unknown\", \"Relative contributions of Sgk1-Mycl vs. RANK-NFATc1 pathways not quantified\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"CTSK was shown to mediate lysosomal degradation of the chemokine CXCL1 in tumor-associated macrophages, suppressing neoangiogenesis—an unexpected non-ECM proteolytic function in immune cells.\",\n      \"evidence\": \"TAM membrane-capture/LC-MS, CXCL1-lysosome co-localization, CXCL1 overexpression rescue, zebrafish and mouse xenograft models\",\n      \"pmids\": [\"41072283\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct cleavage of CXCL1 by purified CTSK not demonstrated\", \"Whether other cathepsins compensate in CTSK-null macrophages is unknown\", \"Single-lab finding awaiting independent replication\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"In osteoclasts, HIF-1α controls lysosomal biogenesis through a TSC2–mTORC1–TFEB axis; conditional HIF-1α deletion in Ctsk+ cells caused disorganized ruffled borders and defective bone resorption, integrating oxygen sensing with CTSK-dependent osteoclast function.\",\n      \"evidence\": \"Conditional HIF-1α KO in Ctsk-Cre mice, DTR transgenic ablation, micro-CT, TSC2-mTORC1-TFEB pathway analysis\",\n      \"pmids\": [\"41108121\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether HIF-1α directly regulates CTSK transcription or only lysosomal compartment biogenesis is unresolved\", \"Relevance under normoxic versus hypoxic conditions in vivo not quantified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the full in vivo substrate repertoire of CTSK beyond type I collagen, whether CTSK enzymatic activity (versus lineage marking) is required for periosteal stem cell function, the structural basis of disease-causing mutations at atomic resolution, and the relative contributions of multiple upstream transcriptional pathways (NFATc1, Mycl, METTL3/m6A) to CTSK expression in different cell types.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No comprehensive substrate profiling by degradomics in vivo\", \"No crystal structure of disease-causing CTSK mutants\", \"Relative pathway contributions in vivo not quantified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 3, 4, 18]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 3, 10, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [0, 12, 18]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [4, 10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [2, 3, 14]},\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [4, 10, 14]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [13, 15, 16]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [7, 12]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7, 8]},\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [12]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"NFATc1\",\n      \"RUNX2\",\n      \"MYCL\",\n      \"METTL3\",\n      \"SGK1\",\n      \"TFEB\",\n      \"SFRP4\",\n      \"CXCL1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"Cathepsin K is a lysosomal cysteine protease of the papain superfamily that serves as the principal collagenase in osteoclast-mediated bone resorption and a key regulator of extracellular matrix turnover in multiple tissues. Its unique collagenolytic activity requires oligomerization with chondroitin sulfate glycosaminoglycans into a pentameric complex (5:5 stoichiometry), in which C-shaped dimers bridged by GAGs bind collagen fibrils at the gap region and unfold triple-helical collagen via residues Q21 and Q92; monomeric cathepsin K retains only gelatinase activity [PMID:12039963, PMID:25422423, PMID:14645229]. Loss-of-function mutations in CTSK cause pycnodysostosis, an autosomal recessive osteosclerosis, by abolishing osteoclastic collagen degradation [PMID:8703060]. CTSK transcription during osteoclastogenesis is cooperatively driven by RANKL-induced p38/NFATc1 signaling in concert with PU.1 and MITF, and by an Sgk1–Stat3–Mycl axis, while beyond bone CTSK maintains ECM homeostasis in lung and synovial fibroblasts and mediates lysosomal degradation of CXCL1 in tumor-associated macrophages to modulate angiogenesis [PMID:15304486, PMID:41266497, PMID:15161653, PMID:11733367, PMID:41072283].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Molecular cloning of cathepsin K established it as a novel papain-family cysteine proteinase with predominant osteoclast expression, answering the question of which protease mediates osteoclastic bone matrix degradation.\",\n      \"evidence\": \"cDNA library screening with rabbit OC-2 probe, Northern blot tissue distribution in human tissues and osteoclastomas\",\n      \"pmids\": [\"7818555\", \"7576232\", \"7805878\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrate specificity not yet defined\", \"No in vivo loss-of-function evidence\", \"Mechanism of activation unknown\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Identification of CTSK mutations as the cause of pycnodysostosis, combined with in vitro demonstration of collagenolytic and osteonectin-degrading activity, linked cathepsin K enzymatic function directly to human skeletal disease and defined its key substrates.\",\n      \"evidence\": \"Genetic linkage and Sanger sequencing in pycnodysostosis families; baculovirus-expressed recombinant cathepsin K tested on type I collagen, osteonectin, and fluorogenic peptides with inhibitor profiling\",\n      \"pmids\": [\"8703060\", \"8647860\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of collagen triple-helix cleavage unknown\", \"No crystal structure yet\", \"Quantitative genotype–phenotype relationship not established\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"The crystal structure of cathepsin K complexed with an inhibitor revealed the active-site architecture, and immunolocalization placed cathepsin K at the osteoclast ruffled border during active resorption, linking structural knowledge to the subcellular site of bone degradation.\",\n      \"evidence\": \"X-ray crystallography of inhibitor-bound cathepsin K; immunohistochemistry and in situ hybridization on bone and giant cell tumor sections\",\n      \"pmids\": [\"9033587\", \"9028530\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How cathepsin K achieves collagenase versus gelatinase selectivity is unknown\", \"No information on cofactor requirements\", \"Genomic regulation largely unexplored\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Discovery that the serpin SCCA1 forms a stable 1:1 inhibitory complex with cathepsin K with rapid kinetics identified the first endogenous cross-class inhibitor, establishing a regulatory mechanism for controlling cathepsin K activity.\",\n      \"evidence\": \"Kinetic analysis with second-order rate constants, stoichiometry measurement, SDS-PAGE detection of stable complex\",\n      \"pmids\": [\"9548757\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological relevance of SCCA1 inhibition in bone or other tissues not shown\", \"Other endogenous inhibitors not surveyed\", \"In vivo consequence of disrupting this interaction unknown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"The requirement for chondroitin sulfate GAG complex formation (5:5 oligomer) for collagenase activity, versus monomeric gelatinase activity, resolved why the Y212C pycnodysostosis mutant retains gelatinase but not collagenase function, fundamentally distinguishing cathepsin K from other cysteine cathepsins.\",\n      \"evidence\": \"In vitro complex formation, collagen and gelatin degradation assays, analysis of Y212C pycnodysostosis mutant\",\n      \"pmids\": [\"12039963\", \"14645229\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the oligomeric complex not yet visualized\", \"Identity of GAG-binding residues not mapped\", \"Whether other GAGs serve as cofactors in non-bone tissues unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"RANKL-induced transcriptional regulation of CTSK was dissected: p38 MAPK phosphorylates NFATc1, which complexes with PU.1 and MITF at the CTSK promoter, explaining how osteoclast differentiation signals converge to activate this effector protease gene.\",\n      \"evidence\": \"Cathepsin K promoter deletion reporter assays, overexpression in RAW264 cells, p38 inhibitor SB203580, nuclear localization studies\",\n      \"pmids\": [\"15304486\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Chromatin accessibility and epigenetic regulation at the CTSK locus not examined\", \"Relative contribution of each transcription factor not quantified\", \"Whether this promoter logic applies in non-osteoclast cell types is unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Demonstration that CTSK-knockout mice develop exacerbated lung fibrosis after bleomycin challenge, with reduced fibroblast collagenolytic activity, established cathepsin K as a homeostatic protease in extracellular matrix turnover beyond bone.\",\n      \"evidence\": \"Bleomycin-induced fibrosis in Ctsk−/− mice, primary lung fibroblast collagenolytic assays\",\n      \"pmids\": [\"15161653\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether cathepsin K acts intracellularly or extracellularly in lung fibroblasts unclear\", \"Specific collagen substrates in lung not identified\", \"Compensation by other cathepsins not assessed\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Structural resolution of the collagenolytically active cathepsin K dimer bridged by GAGs, with mutagenesis proving that Q21 and Q92 mediate collagen unfolding while the dimer interface is essential for fibrillar degradation, provided a complete structural mechanism for collagenolysis distinct from MMP-type collagenases.\",\n      \"evidence\": \"Crystal structure of cathepsin K dimer, site-directed mutagenesis of Q21/Q92 and dimer interface, SEM of collagen fiber binding, Edman degradation of cleavage sites\",\n      \"pmids\": [\"25422423\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full atomic model of the cathepsin K–GAG–collagen ternary complex not available\", \"Dynamics of dimer assembly on the collagen fiber in vivo unknown\", \"Whether the dimer mechanism applies to non-type-I collagens not tested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Ctsk-knockout mice showed delayed osteoarthritis progression with reduced MMP-13 and ADAMTS-5 expression, revealing that cathepsin K not only directly degrades cartilage matrix but also cross-regulates other cartilage-degrading proteases, amplifying joint destruction.\",\n      \"evidence\": \"Ctsk−/− mouse DMM OA model, histologic scoring, IHC for MMP-13/ADAMTS-5\",\n      \"pmids\": [\"21968827\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether cathepsin K regulates MMP-13/ADAMTS-5 transcriptionally or post-translationally unknown\", \"Human OA validation lacking\", \"Relative contribution of osteoclasts versus chondrocytes not resolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"An Sgk1–Stat3–Mycl transcriptional axis was identified as a parallel pathway to NFATc1 for driving CTSK expression during osteoclastogenesis, with Mycl directly binding the CTSK promoter and rescuing differentiation impaired by Sgk1 inhibition.\",\n      \"evidence\": \"Sgk1 inhibitor (GSK650394), Mycl overexpression rescue, Ctsk promoter binding assay, in vivo micro-CT\",\n      \"pmids\": [\"41266497\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of Mycl versus NFATc1 at the endogenous CTSK promoter not quantified\", \"ChIP-seq confirmation of Mycl occupancy lacking\", \"Single lab with single inhibitor\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Cathepsin K was shown to mediate lysosomal degradation of CXCL1 in tumor-associated macrophages, suppressing CXCL1-driven neoangiogenesis, extending cathepsin K's functional roles into immune–tumor microenvironment regulation.\",\n      \"evidence\": \"CXCL1–lysosome colocalization, CTSK expression modulation, breast cancer xenograft and zebrafish angiogenesis models\",\n      \"pmids\": [\"41072283\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether CXCL1 is a direct cathepsin K substrate or degraded via secondary lysosomal proteases not distinguished\", \"Generalizability to other tumor types untested\", \"Single study\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the atomic structure of the cathepsin K–GAG–collagen ternary complex, the in vivo relevance of SCCA1 inhibition, the mechanistic basis for cathepsin K's regulation of downstream proteases (MMP-13, ADAMTS-5), and the full scope of cathepsin K substrates and functions in non-bone tissues such as the tumor microenvironment.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No ternary complex structure\", \"SCCA1 inhibition not validated in vivo\", \"Substrate repertoire beyond collagen I and aggrecan incompletely catalogued\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [2, 9, 10, 11, 19]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [2, 9, 10, 11, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [5, 30, 33]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [5, 10, 14]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [2, 9, 10, 11, 14, 19]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [2, 6, 11, 16]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 8, 18, 24, 35]}\n    ],\n    \"complexes\": [\n      \"Cathepsin K–chondroitin sulfate pentameric complex\"\n    ],\n    \"partners\": [\n      \"SCCA1\",\n      \"NFATC1\",\n      \"PU.1\",\n      \"MITF\",\n      \"MYCL\",\n      \"TFEB\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}